A scoping review on control strategies for

Echinococcus granulosus sensu lato

Tania De la Cruz-Saldana[1,2¶], Javier A. Bustos[1,2¶], Maria P. Requena-Herrera[3], Nelson

Martinez-Merizalde[4], Lizzie Ortiz-Cam[3], Ana Lucía Cáceres[5], Carolina Guzman[1,5], Cesar M.

Gavidia[6], Cesar Ugarte-Gil[7], Ricardo Castillo-Neyra [3,8*].

[1] Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru.

[2] Center for Global Health, School of Health Sciences, Universidad Peruana de Ciencias

Aplicadas (UPC), Lima, Perú.

[3] One Health Unit, School of Public Health and Administration, Universidad Peruana

Cayetano Heredia, Lima, Peru.

[4] School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.

[5] School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.

[6] Facultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima, Peru.

[7] Department of Epidemiology. School of Public and Population Health, University of Texas

Medical Branch, Galveston, Texas, USA.

[8] Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine at

University of Pennsylvania, Philadelphia, Pennsylvania, USA.

*Corresponding author

E-mail: cricardo@upenn.edu (RC)

[¶]These authors contributed equally to this work.

Abstract

Background: Cystic echinococcosis (CE) is a widespread neglected zoonotic disease caused by *Echinococcus granulosus sensu lato* (EG) with a global burden of control in the billions of dollars. *E. granulosus'* life cycle involves definitive, intermediate, and humans as dead-end hosts. Echinococcosis control programs use strategies that focus on any of these hosts. We aimed to provide a comprehensive and up-to-date overview of the EG control interventions worldwide.

Methods: We conducted a scoping review by mapping all studies on interventions for EG control following the Arksey and O'Malley Framework. We screened identified articles, and charted and coded selected papers. We classified the data based on target host, type of study, and control mechanism. We described the efficacy or safety outcomes, and the associated barriers/facilitators for the intervention. Critical appraisal was conducted.

Results: From 7,853 screened studies, we analyzed 45: seven centered on human interventions, 21 on animals, and 17 on both. Studies on humans focused on educational strategies and human CE monitoring. The studies on animals were field trials and most were based on Praziquantel (PZQ) for dogs. Studies focused on both animals and humans had, in general, more participants, lasted longer, and covered larger geographical areas. Overall, the quality of studies was moderate to low.

Conclusions: Available evidence suggests that long-term interventions aimed at both animals and humans can achieve significant reduction in EG transmission, particularly when PZQ treatment for dogs is included. Higher quality evidence, standardization of methodologies, and better reporting on post-intervention outcomes are necessary for drawing stronger conclusions. Further evidence is needed to assess the sustainability and scalability of control measures. Nonetheless, an integrative One Health approach is essential for overcoming the multiple challenges associated with sustaining long-term control efforts for Echinococcosis.

Funding: RCN was supported by the National Institute of Allergy and Infectious Diseases

(grant nos. K01AI139284 and R01AI168291). LOC, JAB, and RCN were supported by the

Fogarty International Center (grant no. D43TW012741). TAD, CG and JAB were supported

by the Fogarty International Center (grant no. D43TW001140).

Keywords: Echinococcosis, Echinococcus granulosus, Neglected Tropical Diseases,

Neglected Zoonotic Diseases, One Health, Zoonoses

Author Summary

Cystic echinococcosis is a disease caused by the parasite *Echinococcus granulosus sensu*

lato. This parasite can be found in specific areas on all continents, especially in poverty-

stricken regions, increasing costs and losses. Some countries have achieved control, but

most are still in the process. Our review provides a clear picture of what we currently know

about these control strategies and points out where more research is needed. It highlights

how the findings can improve control practices by showing what works best and address

practical challenges. The review also identifies gaps in current knowledge and suggests that

comparing different control methods could help find the most effective and cost-efficient

solutions.

Key areas needing attention include increasing support and funding for echinococcosis, as

the disease is often overlooked. More research from different fields is needed to better

understand and manage the disease's complexities. Better and ongoing surveillance is

crucial for maintaining effective control strategies. Finally, comprehensive reviews that bring

together findings from different studies are needed to identify what works best and improve

and combine future control efforts.

Introduction

Cystic echinococcosis (CE) is a zoonotic disease caused by the tapeworm *Echinococcus*

granulosus sensu lato (EG)[1–3]. CE is most prevalent in the Mediterranean area, Eurasia,

North and East Africa, and South America, where the dissemination is closely linked to

home sheep slaughtering and dog feeding raw viscera[4–7]. However, human CE cases are

also reported in the USA[8], Canada[9,10], Europe[11,12], and Japan[13]. High infection rates among

dogs, coupled with socioeconomic and ecological factors, lead to extensive human

exposure[14–16]. The global burden of CE includes 184,000 disability-adjusted life years

(DALYs) annually, human-associated economic losses of $764 million per year[17], and a

global cost for controlling the disease in animals and humans estimated at $3 billion[3].

Inadequate reporting of CE cases due to poor surveillance is also common globally and

prevents accurate estimates of the burden of disease[18]. Despite its widespread distribution

and significant global impact on human health, CE is considered a neglected tropical

disease, more specifically a neglected zoonotic disease (NZD)[19–21]. CE does not receive

enough attention and funding, which results in limited research efforts compared to other

diseases. EG transmission involves mainly canines and ruminants, so research initiatives

and intervention approaches are hindered by intersectoral work, complexities associated

with ecological factors, and intricate economics related to animal husbandry[22]. Controlling

NZDs offers a cost-effective chance to reduce poverty in rural regions where they are most

prevalent[23]. Rural determinants of health involve social, psychological, economic and

spiritual aspects that should be specifically addressed in control strategies[24].

EG has a complex life cycle involving definitive hosts, intermediate hosts, and humans as

dead-end hosts[3,25]. Intermediate hosts, primarily herbivores like sheep, develop larval cysts

in organs such as the liver and lungs after ingesting pastures contaminated with parasite

eggs. Definitive hosts, typically domestic or wild canids, become infected by consuming the

organs of intermediate hosts containing these cysts[3,25]. In hyperendemic regions, it is

common for humans to reside closely with livestock and shepherd dogs, sharing water from

natural sources; however, the evidence supporting infection through contaminated water is

tenuous[26–31]. In these areas, the infected shepherd dogs become the primary source of

infection for both humans and livestock[6,15].

CE control programs primarily aim to stop the transmission of the causative agent to the hosts[18,32]. Strategies targeting definite or intermediate hosts may include regular dog deworming[33,34], dog population control[35,36], improved management of infected viscera[37], sheep vaccination[38], health education programs[39], epidemiological surveillance strategies[40–42], improvement of diagnostic tests and infrastructure[19,43], and integrative One Health initiatives[44], among others. However, a common barrier to effective control programs is the lack of sufficient information needed to design, implement, and evaluate them.

A literature review is essential to identify the effective components of control and elimination interventions, aiding in strategy development and policy formulation. We conducted a comprehensive literature review, using a scoping review methodology, a useful tool in the arsenal of evidence synthesis approaches[45]. Our goal was to identify the scientific rationale, objectives, and efficacy of various interventions, providing a current overview of the current status of EG control interventions worldwide. This study provides new insights for future research and public health efforts for CE control.

Methods

The protocol of this review is registered on the Open Science Framework (www.osf.io) with DOI 10.17605/OSF.IO/48AZR. We mapped all available evidence on interventions for EG control. We followed the Arksey and O'Malley Framework consisting of five stages: (i) Identifying the research question, (ii) Identifying relevant studies, (iii) Study selection, (iv) Charting the data, and (v) Collating, summarizing and reporting the results[46,47,45,48,49].

Identifying the research questions

With this review we aimed to (i) map all evidence available regarding field interventions looking to control, reduce or eliminate echinococcosis in endemic areas and, (ii) identify research gaps that can lead to future studies and, potentially, successful interventions. The following questions guided this review:

1. What strategies have been implemented, piloted, or tested to reduce, control, or

eliminate EG infection in animals and/or humans?

a. What was the rationale for the study/intervention?

b. Who/what were the targets?

c. What barriers and facilitators were encountered?

2. For each intervention found in question 1

a. What was the efficacy/effectiveness outcome?

b. Was there any safety metric/outcome?

c. How long has the program/intervention worked? Is it still in place?

d. What kind of modifications/changes has the intervention undergone over

140   time?

141 Identifying relevant studies

We initially outlined a search strategy for databases and search engines for published data,

followed by reference scanning and gray literature search for unpublished or difficult-to-find

studies. For published data, we included MEDLINE (via PubMed), EMBASE, SCOPUS, Web

of Science, Global Index Medicus and Google Scholar. The search strategy was outlined by

the research team with the support of a librarian. (Appendix 1: search strategy) The search

included all studies until May 2024. The results from all searches were imported and

organized in Covidence™ (Melbourne, Australia), a web-based software platform that

streamlines the literature review process.

150 Study selection

We included all available evidence, including published, preprint, or gray literature,

evaluating interventions to reduce, control, or eliminate echinococcosis by EG infections in

animals and humans. Our search was global; we did not restrict studies by region. We

included publications in English, Spanish, and Portuguese. Studies that included vaccines

as components of field interventions were included. However, studies whose primary

endpoint was to evaluate the efficacy of vaccines or deworming treatment under controlled

conditions were considered out of the scope of this review and were excluded.

We screened the articles in two stages: first, by titles and abstracts, and second, by full-text.

Titles and abstracts were imported into Covidence™ where reviewers assessed eligibility

and filtered duplicates. The final list was evaluated by two pairs of reviewers. Both screening

processes were preceded by a pilot to compare the results of the review teams, align

criteria, and discuss discrepancies to reach a consensus. For quality appraisal, we used the

Mixed Methods Appraisal Tool (MMAT) which allows the evaluation of multiple types of

studies[50].

166 Data charting, synthesis, and reporting results

We used an electronic form/Excel® spreadsheet developed by the research team for the full-

text stage for reviewers referencing, tracking, and documentation of excluded studies. Key

information recorded included, but was not limited to, author(s), year of publication,

methodology, and intervention characteristics. We piloted the abstraction chart to assess

consistency between reviewers and calibrate the chart if needed.

The included papers were divided into types of intervention and classified according to the

associated control mechanism (elimination of parasites, population control of hosts, and

management of sick human/animal population, among others) and their target host. For

each type of intervention, we described the efficacy or effectiveness and the safety outcome,

if available, and the associated variables and the barriers/facilitators found. The results are

presented in figures and tables. For studies with qualitative results, a synthesis of the main

variables is presented.

Quality appraisal

We used the Mixed Method Appraisal tool (MMAT), which allows for the appraisal stage of reviews that include qualitative, quantitative and mixed methods studies. It presents two general questions followed by five sections corresponding to different study designs, each section having five questions that evaluate quality criteria[50,51]. Each question can be answered as "yes", "no" or "can't tell". The "yes" is considered as the fulfillment of the criterion. The tool does not present a cut-off point, so the score of the studies was presented descriptively as suggested by *Reporting the results of the MMAT (version 2018)*[52] as follows:

5***** or 100% quality criteria met

4 **** or 80% quality criteria met

3 *** or 60% quality criteria met

2 ** or 40% quality criteria met

1 * or 20% quality criteria met

In the case of mixed studies, we followed the recommendation of the MMAT manual: we asked a total of 15 questions (5 questions for qualitative studies, 5 for quantitative studies and 5 for mixed studies) and considered the lowest score as the overall quality score.

Results

We found a total of 7,853 potentially relevant studies, with 2,848 from MEDLINE, 2,139 from Scopus, 1,347 from WHO, 828 from Web of Science, 580 from Google Scholar, 108 from Embase, and 3 from gray literature. A total of 1997 duplicates were removed either manually or identified by Covidence. After screening the titles and abstracts, 309 met the eligibility criteria. Subsequently, 264 studies were excluded during full-text review, and finally, 45 studies were included in this scoping review (Fig 1). We mapped these studies across various regions globally, as depicted in Fig 3. Most of these studies were conducted in Argentina and China (n=7, each), where there are high endemicity areas. Other highly endemic areas such as Turkey and Kenya have been the subject of at least one study each.

205 However, several other hyperendemic regions around the world have yet to be represented

206 in the literature.

Interventions in humans

Of the 45 articles reviewed, seven studies reported interventions aimed only at humans

(Table 1a). Six studies primarily focused on education and awareness and one study

focused on CE monitoring. In Portugal, a 13-year program unveiled 62 CE cases via

ultrasound, 24 cases via serology, and 21 cases via both. Health information was provided

to adults, with specific activities designed for children. CE prevalence decreased by 20%

midway through the study and by the end, feeding raw viscera to dogs dropped from 60% to

20%[53]. In Peru, nine educational sessions were applied to 28 school children. A high-level

knowledge of CE increased from 50% to 100% in the intervention group[54]. In Chile, a 7-level

educational intervention run over 4 years for 3,145 participants aged 2 to 20 improved

knowledge at all levels. Compared to urban, rural schools showed greater improvement. The

biggest changes were in knowledge about hand washing, washing fruits and vegetables,

and avoiding dog licking. Knowledge of responsible dog ownership was highest before the

intervention and showed the least change[55]. In the USA, a 73-item questionnaire was

applied to evaluate an educational program, including knowledge and the willingness to

engage in preventive actions. In 8 years, awareness increased from 28% to 83%[56]. In

Turkey, awareness interventions were applied to children, the general public, and health

care professionals. In children, knowledge increased from 5.8% to almost 90%. No efficacy

measure is provided for adults[39]. In Morocco, an integrated health messaging intervention

was implemented including EG, rabies, and other zoonoses. "Piggy-backing" on high priority

diseases like rabies allowed participants to better retain information on EG[57]. In Argentina,

an ultrasound monitoring trial in humans was implemented to support a comprehensive

control program. The trial revealed that prevalence reduced from 5.5% to 4.04%.

Additionally, high-risk groups were identified and this evidence informed program actions[58].

Details about these interventions focused on humans are found in Table 1a.

Table 1a. Interventions in Humans

#	Author, year	Country of study	Study design	Sample size	Inclusion criteria	Main objective	Intervention	Intervention duration	Main outcomes
Trials									
1	**Larrieu E, et al., 1989**	Argentina	Field trial	689 people.	542 asymptomatic volunteers and 147 asymptomatic cohabitants of CE cases.	Control and prevention	Portable ultrasound screening in general public and cohabitants of CE cases that overwent surgery, with a 3-year gap during the nationals control program. Prevalence was reported.	3 years (1984-1986)	Prevalence of CE.
2	**Hernández Mira GM, et al., 2008**	Portugal	Field trial	2,152 people.	Rural volunteers: 780 men and 1362 women.	Eradicate	Tracking of CE cases in three phases. - Phase 1: Epidemiological questionnaires to volunteers. - Phase 2: Obtaining a blood samples for serological testing. - Phase 3: Abdominal ultrasound. This actions included the distribution of informative brochures along with explanation of their content, small informational sessions for general population and specific activities for school-age children.	13 years (1994-2006)	Prevalence of CE. Change in people habits.
3	Pariona-Diaz A, et al., 2018	Peru	Pre post	56 people.	Experimental and control group, both of 28 boys and girls from 5th grade from a public school in Huancavelica.	Prevention	Educative program: 9 in-person sessions of 2.5 hours weekly. The program, using the Bustos operative didactic model, employed various techniques and teaching materials like small group sizes, guidance, active student participation throughout the learning sessions, self-correction of answers by students, and reinforcement at the end of each session. After the intervention a questionnaire of 40 items was applied to assess effectivity.	9-10 weeks	Knowledge level about CE after the implementation of the educational program.

4	**Castillo-Montes M, et al., 2023**	Chile	Pre post	3145 people.	Students from preschool, primary and secondary. All schools from three communes were included.	Prevention and Control	Educative program: First, areas of knowledge about CE were defined and seven educational levels were differentiated by grade of education. A didactic guide with different objectives and methodologies was assigned to each level. Teachers were trained to develop the program in three sessions (initial, profundization, closure). Seven pre and post tests previously validated were applied before the first and after the last session.	5 years (2014-2018)	Changes in the knowledge level about CE after the educational program.

Observational									
5	**Condie S, et al., 1981**	USA	Cross-sectional	People from 156 households.	Adult members of each family from Fountain Green, Utah.	Prevention and control	A 73-item questionnaire was constructed to investigate the impact of an educational-control program. The questionnaire included information about CE and the relationship between antecedent variables and the willingness to engage in six preventive actions: medicating dogs regularly, attending screening clinics, tying up their dogs, preventing dogs from eating sheep liver and lungs, disposing sheep carcasses in covered pits and bury or burn sheep carcasses.	3 weeks (August 1978)	Correlation of attitudes and knowledge, and the willingness to participate in the public health control program.
6	**Ducrotoy MJ, et al., 2015**	Morocco	Convergent	656 people for focus groups. 6910 people for evaluation questionnaire and pop quiz. 33 teachers for evaluation forms. 23 teachers for interviews.	Three groups in rural areas of Sidi Kacem province: - Community, including women, men and children, - School children, and, - Stakeholders, including NGOs, healthcare professionals and local governments.	Prevention	For the community group, educational events focused on rabies, CE, leishmaniasis, brucellosis and bovine tuberculosis. They tried different combinations of these diseases. For events that focus solely on bacterial zoonosis, there was a separation between adults of 21 communes and school children from 23 schooled-bases. Education of stakeholders took place in participatory workshops and 4 education sessions of integrated messaging on all five zoonosis. Evaluation was done in focus groups,	18 months	Pros and cons of the integrated health messaging intervention.

#	Author	Country	Type	Sample	Target groups	Category	Intervention	Duration	Outcomes
							post presentation pop quizzes, and evaluation questionnaires. In schools, evaluation forms were given to teachers and headmasters, and informal interviews were held with teachers.		
7	**Altintas NA, et al., 2021**	Turkey	Descriptive	5208 people.	Three target groups from CE endemic districts: - Elementary school 3rd and 4th year students, teachers and administrators from schools, - General public, and, - Healthcare professionals.	Prevention	Awareness activities: Student adapted presentations were given in 26 schools for students, teachers and administrators. Brochures and posters were distributed. For general public seminars and brochure distribution about CE. Training of healthcare professionals included presentations and distribution of brochures.	1 year (2019-2020)	Number of attendees to the seminars. Knowledge change in school children.

*CE: cystic echinococcosis, EG: echinococcus granulosus

Interventions in animals

We reviewed 21 articles of interventions aimed only at animals (Table 1b). Six interventions targeted both dogs and sheep, 12 targeted only dogs, and 3 only sheep. Most studies were based on the delivery of Praziquantel (PZQ). In Australia, an intervention included testing dogs, treating positive dogs with bunamide at days 0 and 14, and recommendations for home slaughtering. The incidence in dogs dropped from 11.3% to 2.1% in a 4-year period[59]. In Uruguay, different PZQ frequencies in dogs were compared. One year of PZQ treatment every 6 weeks reduced the prevalence in lambs to 0, while in the 12- and 16-week schemes, as well as in the control group, the prevalence ranged from 4.3 to 18.6%[60]. Also in Uruguay, a PZQ-based 9-years control program in dogs reduced the prevalence in dogs from 22.7% to 1.5% and, in 4-year-old sheep from 49.3% to 18.5%[61]. Similarly in Brazil and China, dogs that were treated with PZQ every 30 days had their prevalence reduced from 10.67% to 0.74%[62] and from 7.3% to 1.7%[63] respectively. In Peru, an interesting PZQ regimen was implemented: two treatment cycles were administered to dogs with a 12-month interval between them. In each cycle, dogs received three doses of PZQ, one dose per month. Prevalence in dogs reduced from 47.2% to 1.3%. Unfortunately, prevalence was only evaluated once one month after the last dose[64]. In Argentina, a control program that started in 1980 had multiple modifications. It began with an EG baseline for dogs, sheep, and the environment. Later lambs received EG95 vaccine and multiple boosters. Female sheep got an extra dose for colostral immunity. After 3 years, prevalence in sheep dropped from 26.2% to 7.8%[65]. This program, updated in 2009, was later evaluated through copro ELISA in dogs, necropsy of adult sheep, and ultrasound screening in children. By 2017, infection in 6 y.o. sheep decreased from 56.3% to 21.6%, in dogs from 9.6% to 3.7%, and in children from 38 cases to only one[66]. In the same program, between 2018-2022, in addition to EG95 in sheep, dogs were treated with PZQ 4-times a year. Prevalence among vaccinated and unvaccinated sheep was 21% and 66%, respectively[67]. In Chile, a neighboring country to Argentina, a 3-year program vaccinated sheep with EG95 vaccine at 2 and 3 months old,

and then annually. By the end of the program, cyst fertility dropped from 28.1% to 8%[68].

Another multi-pronged intervention was conducted in Morocco, a 4-year program compared

PZQ for dogs every 4 months, EG95 vaccination of lambs, and both combined. Dog

prevalence dropped from 35% to 9%. Post-intervention, the prevalence of viable cysts in

sheep was 5% with combined intervention, 8% with sheep vaccination, 69% with dog

treatment only, and 77% with no intervention[69].

Cyprus and Norway provided data from hypoendemic areas. In Norway, dogs were treated

with PZQ biannually first and annually in the following years. After 4 years, the prevalence in

reindeer reduced from 1.5% to 0.11%[70]. In Cyprus, infected livestock were identified in

slaughterhouses, dogs were tested using arecoline and coproELISA, and infected dogs were

euthanized and examined or treated with PZQ. Sheep prevalence reduced from 0.033% to

0.007%[71]. Several studies did not report efficacy metrics or reported negative results. In

Kenya, a 16-month control program included dog population control, administering arecoline,

and treating infected dogs with PZQ every six weeks. Prevalence reduced but remained high

and returned to pre-control levels within three months[72]. In Kyrgyzstan, dogs were treated

with PZQ four times for a year. Pre-intervention coproELISA prevalence was 20.1%;

however, post-intervention prevalence was not reported[73]. In China, multiple studies have

been reported. Baits with PZQ were tested to treat dogs and other canids every other month;

however, after 7 months, no significant effect was detected in high-prevalence areas[74]. In

Buddhist areas, where dog culling is not accepted, administering PZQ twice a year for five

years reduced EG prevalence in dogs only from 27% to 20%[75]. In a different study, after 3

years of implanting slow-released PZQ-medicated bars in dogs, copro ELISA positivity in

dogs plummeted from 41.2% to 3%, seropositivity in children reduced from 41.2% to 5.4%,

and prevalence in sheep dropped from 44.8% to 10.7%[76]. Some interventions have explored

innovative approaches. In China, smart collars enabled automatic delivery of PZQ baits to

dogs. Collars also had sensors to provide real-time data that could be used to study trends

of echinococcosis. Post-intervention prevalence was not provided[77]. In Italy, carcass

disposal was enhanced through vulture feeding stations. CE prevalence in sheep was 65.3%

and, though no post-intervention estimates are provided, the authors concluded that the

program reduced CE risk and burden[78]. Also in Italy, GPS data loggers were attached to a

sheep leader and two shepherd dogs to delimit grazing areas. Grazing areas' perimeters

were baited with anthelmintics for free-roaming dogs, proposing another method of control[79].

Details of these interventions focused on animals can be found in Table 1b.

Table 1b. Interventions in Animals

#	Author, year	Country of study	Study design	Sample size	Inclusion criteria	Main objective	Intervention	Intervention duration	Main outcomes
Trials									
1	**Meldrum GK, et al., 1968**	Australia	Field trial	Dogs per years: - 1964/65: 1,552. - 1965/66: 8,013. - 1966/67: 18,900. - 1967: 9,394.	Dogs from municipalities all over Tasmania.	Control, Prevention Reduction	Tasmanian control scheme included a method of testing dogs that involved the use of testing strips on mobile laboratories. Also recommendations were given to owners against feeding offal to dogs and favoring good practices for home slaughters. Obligatory treatment with bunamide of positive dogs and repeated in 14 days.	4 years (1964-1967)	Incidence of EG in tasmanian dogs.
2	**Kummeneje K, el al., 1981**	Norway	Field trial	42,591 reindeer livestock and unknown number dogs.	Reindeer livestock. Dogs from reindeer owners.	Eradication	Systematic PZQ treatment of dogs owned by reindeer breeders and posterior public meat inspection of reindeer.	7 years (1975-1981)	Prevalence of CE in reindeer meet before and after the introduction of dog PZQ treatment.
3	**Macpherson CN, et al., 1986**	Kenya	Field trial	452 dogs.	Dogs from rural areas.	Control	The program included registration of owned dogs, elimination at owners request and of stray dogs, dosing of identified dogs every 6 weeks with PZQ, dosing with AB, spaying of female dogs and elimination of infected owned dogs by owners petition.	16 months	Proportion of registered dogs dosed. Number of destroyed dogs.
4	**Economides P, Christofi G, 2000**	Cyprus	Field trial	15,528 dogs. 6,103,649 livestock (cattle, sheep, goats and pigs).	Stray dogs and farm dogs from 48 villages and infected livestock from 79 villages.	Control and Eradication	Detection of infected livestock during slaughter by cysts identification and testing of dogs from the infected location. Treatment of infected dogs with PZQ baits. Euthanasia of infected stray dogs and postmortem examination. Additionally, records of human CE cases in government hospitals reported in an unpublished study are referred to observe the dog-	7 years (1993-1999)	Incidence of infection in dogs and livestock.

						human transmission.		
5	**Cabrera PA, et al., 2002**	Uruguay	Field trial	Section 1: 71 dogs and 1036 sheep. Section 2: 451 dogs and 1013 sheep. Section 3: 476 dogs and 696 sheep. Section 4: 237 dogs and 907 sheep.	The area selected was divided in 4 sections that included farms and houses from rural and urban places.	Control	Section 1: no control and continued with the national education program. Owners were free to dose their dogs with PZQ. Sections 2-4: dogs were recorded and treated PZQ every 6, 12, 16 weeks for each section. Sentinel lambs were purchased from farms, followed and examined upon death. Sheep slaughtered for human consumption were also examined for CE. T. hydatigena and ovis were also recorded.	2.5 years	Transmission of EG to sentinel lambs as the mean number of cysts per infected sheep, % of farms infected and % of sheep infected.
6	**Farias LN, et al., 2004**	Brazil	Field trial	First evaluation: 65 dogs. One month after the last treatment: 61 dogs.	Dogs in rural, suburban and urban areas.	Control	Each dog was treated with PZQ regardless of their diagnostic results after first purgation and every 30 days until the 8th month. Purging dogs with AB to observe the presence of EG and coproELISA before and after the treatment. Property owners were asked about treating their dogs, letting them eat raw viscera and open slaughtering facilities.	1.7 years (2001-2002)	Infected dogs before and after PZQ treatment.
7	**Oku Y, et al., 2004**	Uruguay	Field trial	Before the program: 79 town dogs, 208 farm dogs and 639 sheep. After the program: 375 sheep.	Town and farm dogs. Sheep viscera from slaughterhouses.	Control	A change in the control program included treatment with PZQ monthly to all dogs. Before the program dogs were examined for adult stage of cestodes by necropsy and fecal examination. Sheep, both before and after the program were examined for cysts.	9 years (1991-1999)	Prevalence of EG in dogs, before the control program. Prevalence of CE in sheep before and after the control program.

#								
8	**Wei J, et al., 2005**	China	Field trial	603 dogs in 2000.	Dogs from twenty two villages from two experimental areas, one from an agricultural region and the other from a pastoral region from epidemic areas in the north of Xinjang and an adjacent country with similar conditions for the control area.	Prevention and control	Type SRP III slow release medicated hypodermic bars containing 500 mg of PZQ were implanted in dogs. Then coproELISA was used to detect EG in dogs every year. Serum antibody was used to screen new pupils in a primary school in all the areas and portable ultrasound for children aged 7-16 years in the experimental areas. Also, surveillance in one year old lambs from the experimental areas were inspected for EG metacestodes in slaughterhouses.	3 years (2002-2003)	EG prevalence in dogs at the start and annually. Prevalence of CE in new primary school pupils and school children. Prevalence of CE in sheep.
9	**Yang YR, et al., 2009**	China	Field trial	4,263 owned dogs. 1,500-2,000 stray dogs.	Dogs from an agricultural area.	Control	Dogs were treated with PZQ twice a year. Dogs from selected households were tested with coproELISA after each treatment. Unwanted dogs were euthanized and inspected for EG worms. Yaks, sheep and goats were examined for cysts. Human and animal cysts were sequenced for *apt6* gene.	6 years (2000-2005)	Prevalence of EG in dogs. Prevalence of CE in sheeps and goats. Characteristics of cysts in yaks. DNA analysis of cysts.
10	**Larrieu E, et al., 2013**	Argentina	Field trial	Control area: 7,128 sheep, 1,550 lambs and 141 dogs. Vaccination area: 9,383 sheep, 3,146 lambs and 311 dogs.	150 farms from different regions in Rio Negro.	Control	Before vaccination, 109 farms were selected for a baseline survey at random and tested with coproELISA/WB (dogs), ELISA/WB (lambs) and PCR (soil). Also necropsies from purchased animals > 6 years, and dogs purgation with AB were done. Sheep from 71 farms were the control group, and, from 79 farms received 2 immunizations with EG95 (1st dose at 30 days of age and 2nd at 60 days of age) and a booster at 1-1.5 years of age. Additionally, 13 (all female animals) from one region were vaccinated with one dose for 2 months period to generate colostral immunity in lambs born after vaccination. Impact after vaccination was compared between the vaccinated and control groups.	3 years	Vaccination rates and diagnosis of EG after the introduction of EG95 vaccine.

11	Van Kesteren F, et. al., 2017	Kyrgyzstan	Field trial	2013: 191 dogs. 2014: 193 dogs.	Dogs from 10 Alay Valley communities.	Control	Pre intervention of coproELISA prevalence was determined, followed by intervention of deworming with PQZ 4 times a year. Local knowledge of CE was measured. PZQ dosing and the impact of the intervention on coproELISA prevalence were evaluated.	1 year (2013-2014)	Pre and post intervention coproELISA prevalence. Evaluation of PZQ dosing.
12	Yu Q, et al., 2017	China	Field trial	Unknown.	Wild canines from 2 pilot areas with a total coverage of 0.48 km2.	Control	Two pilot areas, one with manual delivery other with unmanned aerial vehicle delivery. GPS was used to locate and synchronize point for bait. Bait consisted of 8 beats of 50 mg of PZQ (400 mg PZQ in total). Fecal samples were collected in same place of bait.	6 months	Exploratory outcomes included time consumption and labor, cost of baits and deworming outcome in fecal samples.
13	Larrieu E, et al., 2019	Argentina	Field trial	8,483 sheep. 309 dogs.	Sheep and dogs from areas from Mapuche native communities in the province of Rio Negro.	Control	EG95 vaccine was used in lambs at 30 days, 60 days and 1–1.5 years old. The program's effectiveness was monitored through various methods, including arecoline test, coproELISA testing and Western blot in dog fecal samples, and ELISA from sera & necropsy of adult sheep. The study also screened children using ultrasound.	8 years (2009 - 2017)	Sheep vaccination rates. Diagnosis of EG in dogs and sheep after the introduction of EG95 vaccine.
14	Amarir F, et al., 2021	Morocco	Field trial	797 lambs. 6,545 dogs.	Young female lamb from 32 sheep breeders and owned dogs.	Control	Two different settings took place: In the first one, dogs received 4-monthly treatment with PZQ. In the second, no treatment was given to dogs. Lambs in both cases were randomly allocated in the vaccination or the control group. The vaccination of sheep required two doses, at 2 months old and 1 month later with the EG95 vaccine. They were followed for 4 years with ante mortem ultrasounds or post-mortem dissection.	3.3 years (2015-2019)	Annual incidence risk for each group.

15	**Berlinguer F, et al., 2021**	Italy	Field trial	445 griffon vultures	Griffon vultures in an open hilly area where a 4% of European ovine population is present.	Control and prevention	Controlled disposal of caprine, bovine and equine carcasses in implemented supplementary feeding stations, known as "vulture restaurants".	6 years (2015-2020)	Biomass produced from animal cadavers. Costs saved from incineration and carbon emission.
16	**Yang S-J, et al., 2021**	China	Field trial	523 dogs	Dogs from pastoral areas of three provinces of China.	Control and surveillance	Remote management system based on internet of things as a novel tool to control smart deworming devices to deliver efficient PZQ baits to dogs regularly and automatically and also as a smart digital management platform to monitor, analyze, and display the epidemic trends of echinococcosis dynamically, in real time.	6 months (2019-2020)	Remote management system performance parameters.
17	**Gädicke P, et al., 2022**	Chile	Field trial	1st assessment: 223 sheep. 2nd assessment: 200 sheep.	A commune of predominantly Pehuenche indigenous people: 9 localities across for the first assessment and 10 localities for the second one.	Prevention	Administration of EG95 vaccine at 2 months and 1 month after the first dose. Although most received it at 3 months and without the 1 month booster. Sheep 2-4 years old were examined for cysts before and after the vaccination.	5 years (2016-2020)	Frequency of infection and fertility of cysts after vaccination compared to frequency of infection before.
18	**Labanchi JL, et al., 2022**	Argentina	Field trial	3,898 ovine. 3,934 caprine. 221 dogs. 58 owners.	Indigenous reservation areas.	Control	EG95 vaccine in 2 initial doses one month apart starting at 30 days old and a booster around 1-1,5 years old. Sheep and goat CE diagnosis by necropsy and serology (ELISA). Dogs were dosed with PZQ 4 times a year. Surveys among farmers about slaughter habits for human consumption.	5 years (2018-2022)	Prevalence in adult goats and sheep. Sheep vaccination rates.
19	**Montalvo R, et al., 2022**	Peru	Field trial	252 dogs	Owned and stray dogs.	Control	At the start of the intervention, fecal samples from owned dogs and stray dogs were analyzed by microscopic examination and coproELISA. Dogs received two 3-dose cycles of PZQ every 30 days in a 2 year period. Stray dogs were dosed combining PZQ with bread or chicken and identified using	2 years (2018-2019)	Prevalence of EG in dogs before and after the intervention.

						photos. Prevention messages and informative material were provided to owners in each home visit. Stool samples were collected and analyzed one month after the last PZQ dose.		
20	**Wang L, et al., 2022**	China	Field trial	2017: 184,564 dogs. 2018: 175,561 dogs. 2019: 171,754 dogs.	Domestic and stray dogs from 74 CE endemic districts.	Control	Collection of data on domestic dog registration and deworming. Dog owners embedded PZQ in food to give dogs and recorded it on a logbook every month. Stray dog sheltering. Fecal samples from domestic dogs randomly collected to identify echinococcus using coproELISA.	3 years (2017-2019)	Number of domestic dogs registered. Stray or infected dogs arrested or sheltered. Dog infection rates.
21	**Nocerino M, et al., 2024**	Italy	Field trial	Approx. 200 sheep and dogs per each farm.	Sheep and dogs from 40 sheep farms.	Control	All sheep were tested by ultrasound and post-mortem examinations. There were 5 control farms and 5 CE positive farms received the following interventions. Dogs were treated with chewable tablets of PZQ and milbemycin oxime every 2 months. After 48h fecal samples were collected individually using the Fill-FLOTAC and analyzed by copromicroscopy. If a sample was positive to Taeniidae eggs, rt-PCR was used to detect EG. Three types of GPS data logger collars were attached to the "flock-leader" sheep and to two shepherd dogs to monitor their movements for 1 month. The area of movement was delimited, and the perimeters were baited with anthelmintic for stray or unowned dogs near the grazing area.	Not specified	Prevalence of EG in dogs. Identification of points dor PZG delivery. Spacial-temporal distributions of sheep and dogs.

*AB: arecoline bromhidrate, CE: cystic echinococcosis, EG: echinococcus granulosus, PZQ: praziquantel

Interventions in animals and humans

We reviewed 17 articles focused on both animals and humans (Table 1c). Multiple long-term programs and short-term studies are reported from South America and described integrated interventions dosing dogs, vaccinating sheep, educating and screening humans, and enhancing abattoir surveillance. In Argentina, dogs received PZQ more frequently in high-risk areas and were monitored using arecoline and in-situ analysis. Education was provided to schools, homes, and to rural populations through accessible media. Sheep were inspected at abattoirs and surveillance data collection improved. After two years, dog prevalence decreased from 31.5% to 4.24%[80]. After 17 years of implementation, new human cases in children under 11 decreased by 77%[81]. Also in Argentina, ultrasound surveys in children and copro ELISA surveys in dogs were used to identify hotspots of transmission and strengthen control program activities (education, diagnosis and treatment in humans, deworming of dogs, and vaccination of sheep). Dog prevalence reduced from 32% to 15.6%[82]. In Uruguay, a rural intervention included monthly PZQ plus broad-spectrum anthelmintics 1 to 3 times a year, copro ELISA diagnosis, free dog castration, and ultrasound diagnosis for people. Ultrasound training and EG education were provided at health centers and routine surveillance was conducted in abattoirs. Over five years, dog prevalence dropped from 10% to 1.6%[35]. In Chile's Aysen region, from 1982 to 2001, dogs were usually dosed every 6 weeks. Human prevalence decreased from 75% to 32% and sheep prevalence from 90% to 9%. In 2020, sheep vaccination was added, and surveillance was enhanced by examining sheep cysts and by communities reporting cysts via WhatsApp. Cyst size was negatively correlated with vaccination status[83]. In another study in Chile, infected dogs were identified and treated with PZQ. Health education was provided to farm family members, and they were asked to pledge to educate their neighbors, to practice what was learned, to buy PZQ as a group for their dogs. Serology was conducted on dog-owners. Unfortunately, only pre-intervention prevalence was reported[84]. In the US, a decade-long control program in Utah involved PZQ treatment for dogs (frequency unspecified),

educational initiatives through press releases, filmstrips, and children's coloring books, diagnostic clinics for humans and dogs, and surveillance and proper disposal of viscera at abattoirs. Over seven years, infection rates in dogs dropped from 28% to 1%, but later rose to 10% due to some dog owners' noncompliance. Concurrently, EG infection in sheep steadily declined, and public knowledge about the disease significantly increased[85].

Studies and programs from other parts of the world used a similar integrative approach. In New Zealand, a 21-year program involved treating dogs regularly with arecoline, banning raw offal feeding, and promoting safe sheep slaughtering practices. The authors used the age at which 20% of lambs had 'parasitic' liver damage as an efficacy metric. Over the trial, this age increased from 4 to 9 months[86]. In Cyprus, education was carried out over 5 years, targeting school children, housewives, and dog owners. Dogs were screened and infected dogs were euthanized or arecoline was given according to the owner's consent. After three years, dog prevalence dropped from 50% to 6.8%[87]. In Wales and Morocco education alone was compared to education plus PZQ. In Wales, after the intervention, lamb prevalence was 4.3% in the education area, 6% in the education plus PZQ area, and 10.4% in the control area. Education significantly increased PZQ usage among farmers[88]. In Morocco, an integrated intervention targeted dog rabies, echinococcosis, and canine leishmaniasis. Dogs were treated 3 times a year and purged with arecoline at the end of the study. Dogs receiving PZQ had lower infection rates than those in the only education arm, but the difference was not statistically significant. Education increased knowledge but did not affect risky behaviors[89]. In Spain, dogs were treated with PZQ every 6 weeks for 6 years, health education targeted high-risk groups for the first 3 years, and stray dogs were removed. Sheep were inspected and sanitary pits were provided to dispose of carcasses. New human cases decreased from 19 to 4 per 100,000 people[90]. Also in Spain, a comprehensive program is reported though it lacks detailed descriptions of each component. Nonetheless, the program achieved an overall efficacy of 67% and, importantly, reported a profitability of

970%[91]. In China, in hyperendemic areas a combination of monthly PZQ, culling unwanted

dogs, restructuring and training of the EG management teams, and public education

reduced prevalence in dogs from 14.7-18.6% to zero after 4 years[92]. Another intervention

consisted of education, improved sanitation, ultrasound screening of humans, surgical and

albendazole treatment, and management and monthly PZQ for dogs. Interestly, the authors

report measures of efficacy different from disease burden. After 11 years, surgeries rose by

32.4%, albendazole treatment by 81.3%, and dog deworming by 58.6%[93]. In Italy, an 8-year

program used sentinel sheep abattoirs, analyzed national slaughterhouse data annually,

treated farm dogs with PZQ, and diagnosed dogs with molecular and fill-FLOTAC

techniques. Livestock were diagnosed with ultrasound and human CE surveillance was

based on medical records. Public health education was delivered through multiple media

formats. The program reduced sheep prevalence by 30%, and all dogs were negative 50

days post-PZQ[44]. In the Falklands, legally imposed control activities between 1965 and 1981

included purging dogs, banning offal feeding, and enforcing shepherd dog movement

restrictions. Dogs were treated with PZQ every 6 weeks. Education was conducted through

various media formats. Sheep prevalence dropped from over 40% to below 1% by 1993[94].

Details of these interventions focused on animals and humans can be found in Table 1c.

In Fig 2, we illustrate the points within the EG life cycle where different studies aimed to

interrupt transmission. As numerous studies implemented multiple interventions targeting

various components of the life cycle, the count of interventions depicted in Fig 2 exceeds the

total number of papers analyzed.

Table 1c. Interventions in Humans and Animals

#	Author, year	Country of study	Study design	Sample size	Inclusion criteria	Main objective	Intervention	Intervention duration	Main outcomes
Trials									
1	**Gemmell MA, 1968**	New Zealand	Field trial	Approx. 20,000 sheep, 60 dogs and people in the area.	11 farms in an isolated area with certain natural boundaries.	Control	In the 1st period, for 9 years, all dog owners were requested not to feed any raw offal to dogs and dogs were treated with AB every 3 months. Farmers were advised to build dog-proof sheep killing facilities and burying carcasses. In the 2nd period of 6 years, there was no supervision of dog dosing, but AB was available. In the 3rd period of 6 years, dogs were dosed with AB every 3 months and feces were examined for tapeworms. Additionally modern mass media education and distribution of posters and brochures was done.	21 years (1943-1963)	Efficacy metric: age at which 20% of lambs had 'parasitic' liver damage.
2	**Polydorou K, 1977**	Cyprus	Field trial	Approx. 45,000 dogs at the start of the campaign and people in the area.	Owned and stray dogs, and people from 39,473 households of 600 villages on an island.	Eliminate	Education to the public through mass communication media, establishment of mobile exhibitions, lectures, and others. Also training of government employees, slaughterers and farmers. Dog control by extermination of stray dogs, spaying of bitches, registration and annual fees for owned dogs, and surveillance (mobile and static laboratory testing screening and diagnosis at owners request). Control of slaughter by legislations to require abattoirs to be approved, inspection of viscera and adequate disposal of infected viscera.	15 years (1971-1985)	Improvement of people's preventive practices. Eliminated stray dogs. Infection rates in dogs. Number of spayed bitches. Rates of infected slaughtered animals. Functioning abattoirs.
3	**Andersen F, et al., 1983**	United States	Field trial	Approx. 1950 dogs and 90,400 sheep. 49 coyotes. 74 deer.	Dogs and sheep from an agricultural area.	Control	Education was attained through press releases, distribution of pamphlets, talks with civic and church groups, counseling during screenings and children adapted filmstrip and coloring book. Pre and post tests were applied to students before and after receiving the coloring book. Prophylactic treatment of dogs with bunamidine hydrochloride in 1974-1978 and PZQ in 1979-1981. Surveillance: Dogs were purged with AB and examines on site. Sheep were checked for cysts by state meat inspectors and if suspected,	11 years (1971-1981)	Infection rates in dogs and sheep. New cases in humans. Attitudes and practices of dog/sheep owners. Efficacy of coloring books in school children.

#	Author	Country					Description	Duration	Outcomes
							confirmed in a parasitology lab. Coyotes and deer were examined to assess them as sylvatic reservoirs. Immunodiagnostic clinics for people were usually held with dog clinics.		
4	**Gimeno Ortiz A, et al., 1991**	Spain	Field trial	2,544 dogs. Unknown number of livestock and humans.	Stray dogs, livestock in slaughterhouses and people from the provinces of Cáceres and Basajoz of Extremadura.	Control	A control program was implemented including health promotion through education activities; fight against human CE by enhancing case studies, maps and coordination between health centers; fight against animal CE by improving slaughterhouse infrastructures, inspections and confiscations, and control of livestock and wildlife movement; and, fight against animal echinococcosis by strengthening canine census, stray dog elimination and anti-parasite treatment each 4 months. Additionally they did an economic evaluation.	7 years (1983-1990)	Canine echinococcosis incidence. Stray dogs captured, escaped, eliminated, tested, given back or adopted. Incidence of CE in livestock. Incidence of human CE. Economic loss of CE.
5	**Larrieu E, et al., 1994**	Argentina	Field trial	Approx. 110,468 people, 5,322 dogs at the start of the program.	Urban and rural areas.	Control	Control program with focus on community participation including systematic deworming of dogs with PZQ, surveillance of infection rates in dogs through diagnostic deworming with AB, educational activities in schools, use of mass media for communication, determination of sheep parasitism in slaughterhouses and identification of human CE cases.	13 years (1979-1998)	Reduction in the prevalence of EG in dogs, sheep and humans.
6	**Lloyd S, et al., 1998**	Wales	Field trial	152 lambs, 336 dogs and farmers.	2 lambs and all dogs from each of 76 farms. Farmers from 263 farms. All from three rural areas.	Control	Lambs were purchased from farms of three areas. Area I, received educational and an anthelmintic control program and transmission had stopped previously. Area II, received educational interventions. Areas III, didn´t receive previous interventions. Sheep were slaughtered at approx. 15 months of age and examined for cestodes and lesions were processed histologically. Dogs in all farms were sampled 9 months into the grazing period by coproELISA. Farmers answered a questionnaire about control of sheep diseases, dogs and cats, and sheep movement.	7 years in Areas I and II (1983-1989) Unknown in Area III (1989-?)	Rate of infected/examined sheep. Rate of dogs positive in coproELISA. Owners reporting deworming of dogs.

7	**Apt W, et al., 2000**	Chile	Field trial	5,566 people and 2,358 dogs.	Dogs present in each house excluding puppies and pregnant females. People older than 3 years old for CE screening. Farm families, and healthcare, agriculture and education professionals	Prevention and Control	Serological and radiological diagnosis of asymptomatic people, and surgical treatment. Surveillance of dogs by AB purging and visualization of strobilliar form of EG. Dog treatment with PZQ. Interviews to the head of farm families about family and personal history, and knowledge, habits and practices related to CE. Educational interventions for farm families were held for at least one member through games. Pre and post tests were applied. Educational interventions with healthcare, agriculture and education professionals.	5 years (1992 - 1997)	Identification of CE prevalence in the asymptomatic general population and EG in dogs. Knowledge in farm families.
8	**Larrieu E, et al., 2000**	Argentina	Field trial	11,915 dogs. Population of 596,154 people.	Rural dogs 13 departments from the Río Negro province were included, with a population of approx.. 596,154 people.	Control	Dog registration and PZQ treatment every 60 days in rural and 180 days in urban areas, distributed by owners. Surveillance of dog infection with AB purging. Slaughterhouse surveillance of sheep infection examining viscera. Human CE records and follow-up of new cases in public hospitals, screening blood test or ultrasound. Educational plan including healthcare seminars, home visits, and information for elementary schools.	17 years (1980-1997)	Prevalence of EG and CE in animals and humans. Annual incidence of CE cases.
9	**Jimenez S, et al., 2002**	Spain	Field trial	9,724 dogs, 6,764 sheep for examination at the start of the program. Dogs from 553 to 1,040, and sheep from 376 to 1,172, examined annually during the program. Human population during the program.	Dogs involved with sheep raising for treatment. Autopsied dogs were given up to program authorities or collected stray and rejected dogs. Sheep upon slaughter.	Control	Treatment of all registered dogs with PZQ every 45 days, for 6 years. Intense health education campaigns to risk groups during the first 3 years. Municipalities identify and impound stray and unwanted dogs and examine them by autopsies. Inspection of cysts in sheep. Provision of sanitary pits for disposal of dead sheep. Mean annual incidence of CE in humans was estimated.	14 years (1987-2000)	Annual EG prevalence in dogs, humans and sheep.

10	**Zhang W, et al., 2009**	China	Field trial	Area 1: - Start: 15,990 dogs. - End: 14,684 dogs. Area 2: - Start: 13,322 dogs. - End: 14,230 dogs.	Dogs from two hyperendemic areas.	Control	A village hydatid disease control officer registered dogs to be treated monthly with PZQ. A booklet about CE was distributed and television educational programs were transmitted before treatment. Dogs were purged with AB to estimate EG prevalence. Stray and unwanted dogs were eliminated. Sheep livers and lungs were examined for monitoring in slaughterhouses. Leaders and staff included in the control program were trained and officers received specialized workshops.	3 years in one area (1987–1990) 4 years in the other area (1990-1994)	Efficacy of the pilot program using dog and sheep.
11	**Irabedra P, et al., 2016**	Uruguay	Field trial	Over 220,000 dogs and 87,536 people.	All dogs and population from rural areas, small towns and with risk factors suburban areas.	Control	Diagnosis in dogs using coproELISA test. Dogs were treated with PZQ every 30 days. Since 2008 treatment included broad-spectrum anthelmintic (pyrantel pamoate + PZQ + febantel) once a year to all registered dogs and three times a year in areas with critical socio-economic contexts, with risk of other parasitosis. Control of dog population by free surgical castration in both genres. In 2013 microchips were used to identify spayed dogs. Diagnosis in humans using ultrasound surveys. Health education using verbal and visual methods. Surveillance in livestock from slaughterhouse data.	6 years (2008-2013)	Prevalence of EG in dogs. Mean of dogs treated with PZQ and broad spectrum anthelmintic. Prevalence of CE in people tested with ultrasonography. Prevalence of CE in livestock.
12	**Arezo M, et al., 2020**	Argentina	Field trial	1,780 dogs and 34,515 children.	Owned dogs from sheep farms and school children between 6-14 years.	Surveillance	CE surveillance in livestock farms through dog stool testing with coproELISA. Ultrasound screening for CE in school children. Data was used to create hot spots of CE.	3 years in the first period (2003-2005) 2 years in the second period (2009-2010) 2 years in the third period (2017-2018)	Identification of risk areas.

13	El Berbri I, et al., 2020	Morocco	Field trial	6,922 dogs and 2,885 people.	Dogs and people from 22 communes, mostly rural.	Control	Integrated control intervention for rabies, canine leishmaniasis and CE. Registration of owned dogs. The control group received only rabies vaccination and an educational campaign. The intervention group received rabies vaccination, anti-sand-fly insecticide collar, deworming with PZQ (month 0, month 6 and month 12), and educational campaign. Sampling for leishmanial, AB purging and health education evaluation in both groups.	13 months (2013-2014)	Number of registered dewormed dogs. Prevalence of EG in dogs. People knowledge changes. Cost estimates.
14	Yu Q, et al., 2020	China	Field trial	173,679 people and 2,691,434 dogs.	Registered dogs and patients diagnosed with CE, alveolar echinococcosis, or both, from pastoral and farming pastoral regions.	Control	Health education, sanitation improving, ultrasound screening of the human population, surgical interventions and treatment with albendazole. Also deworming registered dogs with monthly PZQ. Economic analysis of the national program.	11 years (2004-2014)	Proportion of patients medical or surgically treated. Dewormed registered dogs. Cost analysis.
15	Cringoli G, et.al., 2021	Italy	Field trial	Phase 1: 549 dogs. Phase 2: 1,336 dogs. 417 sheep, 125 goats, 383 cattle and 557 water buffaloes. 168 CE patients.	Dogs from sheep farms. Livestock from slaughterhouses. CE patients from hospital discharge records from 2016-2018.	Control	Active and passive surveillance in livestock using geospatial tools for georeferencing. Diagnosis in dogs using the fill-FLOTAC recollection techniques and molecular analysis. Targeted treatment of farm dogs with PZQ, using purpose-built confinement cages. Early diagnosis in livestock by ultrasonography and post-mortem surveillance in slaughterhouses. Surveillance of CE cases hospital discharge records. Analysis of raw vegetables. Dissemination of educational material to the general public like brochures, gadgets, videos and virtual reality.	5 years in Phase 1 (2010-2015) 3 years in Phase 2 (2016-2018)	CE prevalence in dogs and sheep.

| 16 | West D, 2021 | Falklands | Field trial | Unknown number of dogs, sheep and people, | Owned dogs, butchered sheep and people on the island. | Eradicate | Tapeworm Eradication Order No.1 (1965) was implemented by purging dogs with arecoline acetarsol. Order No.2 (1970) involved restrictions on feeding dogs offal and purging with bunamide hydrochloride. Also restricted dog movements near slaughterhouses and enforced fines for breaking this order. Hydatids Eradication Order (1975) enforced the disposal of offal in dog proof containers and banned them being fed to dogs. Fined dog movement restrictions. In 1977, PZQ dog dosing every 6 weeks was implemented. Also, public education which included slide shows, pamphlets and a news sheet called "Hydatid news", released for 6 years. Hydatids Eradication Order (1981) combined the previous orders. Dog dosing with PZQ every five weeks in 2010. Sheep were inspected in slaughterhouses and veterinary offices. | 1970-present | Prevalence of CE in sheep. |
| 17 | Chacón T, 2023 | Chile | Field trial | Unknown number of dogs, sheep and people, | Dogs, sheep and people in the Aysen region. | Control | A control program was implemented from 1982-2001 including dog deworming every 45 days, sanitary education, slaughter control and surveillance in slaughterhouses and dogs by purging with AB. Another plan in 2020-2022 included sheep vaccination and deworming of dogs and sheep, sanitary education, reinforcement of diagnosis capacities involving the community by using WhatsApp groups. Identification of dogs with microchips and sheep with electronic earrings. | 19 years (1982-2001) 3 years (2020-2022) | Rate of infected/examined sheep. Rate of dogs positive in coproELISA. Owners reporting deworming of dogs. |

*AB: arecoline bromhidrate, CE: cystic echinococcosis, EG: Echinococcus granulosus, PZQ: Praziquantel

Quality Appraisal

Of the 45 studies in our review, 40 were evaluated with the quantitative non-randomized studies questions (section 3 of MMAT). The average fulfillment with the quality criteria was 57%: five studies[59,70,83,86,91] did not meet any criteria or their compliance could not be determined, three[58,71,88] met 20%, one[84] met 40%, 16 studies[44,54,61,62,65,72,73,75,78,80,81,87,89,90,93,94] met 60%, 14 studies[35,55,61,63,64,66,67,74,76,77,79,82,85,92] met 80%, and only one study[68] met 100% of the quality criteria. The main criterion for noncompliance/undetermined compliance was the evaluation of possible confounding factors; only one study[68] fully addressed them. The second most frequent challenge was determining representativeness; sampling estimates or clear description of sample selection were not always provided. Another criterion with inadequate or undetermined answers was completeness of the outcome data. Three studies were evaluated with the quantitative descriptive study questions (section 4 of MMAT). The average overall quality was 47%; one[39] met 20% of the criteria, one[53] met 40%, and one[56] met 80%. The main criterion for compliance was the evaluation of risk of nonresponse bias and we found that the information provided was insufficient to comply with the criterion. The second most frequent problem was evaluation of representativeness. The three studies described their target population and eligibility, but in two[39,53] it was difficult to determine if their sample was representative. One study[69] was evaluated with the quantitative randomized controlled trials questions (section 2 of MMAT), and it met 60% of the quality criteria. In this study, the information provided was insufficient to fully evaluate if the randomization was appropriately performed and no information about blinding was provided. One study[57] was evaluated with the mixed methods study questions (sections 5, 1 and 4 of MMAT) and met 40% of the overall quality criteria. This mixed methods study had a predominance of qualitative methods and results. When evaluated by components, it scored 100% of compliance in the qualitative criteria (section 1), 60% in the mixed methods criteria (section 5) and 40% in the quantitative criteria (section 4).

Discussion

We mapped and analyzed 45 articles on interventions for the control, prevention, or elimination of EG from all regions (Fig 3). The primary goal of control interventions is to halt the transmission of EG to its hosts. Compared to earlier interventions[72,86,87], recent advances have significantly enhanced EG control. Key developments include the incorporation of the EG95 vaccine for sheep[95], improved diagnostic techniques for early detection in dogs (e.g., ELISA)[96,97], and the use of PZQ for dog treatment[98]. Despite these advances, progress in EG control remains inconsistent, with mixed results reported[99], and overall, limited advancement in endemic regions[100–102]. We found heterogeneous and generally low quality articles, often lacking clear post-intervention outcomes, which hampers the ability to inform future interventions. Studies varied in scale but provided limited information for scale-up implementation or replication in different settings. Common barriers are often mentioned, but few studies explore real-world barriers and facilitators in depth or address the feasibility of interventions. Additionally, implementation costs are rarely reported, yet cost-benefit analyses are essential for the scalability and sustainability of these strategies[103–105]. In addition, effective EG control requires collaborations, partnerships, and community engagement. The educational interventions we reviewed here were aimed at increasing awareness and knowledge among various stakeholders[39,54–57], but did not report measures of long-term impact. However, the primary value of these interventions may lie in promoting community engagement, which is crucial for the success of control and elimination efforts[106,107]. Future studies could aim at building and examining stakeholder and community engagement for enforcement and sustainability of control activities.

Among the reviewed studies, those focused solely on interventions on animals were the most numerous, while studies focused solely on interventions on humans were the fewest. However, studies focused on both animals and humans had, in general, more participants, lasted longer and covered larger geographical areas. The majority of these articles on integrated strategies described national multi-pronged programs including population

screening and diagnosis, sanitation improvement, human and animal treatment and

surveillance, among others. However, most of these articles came from a few countries who

have been able to sustain these massive efforts to control EG. However, a significant

challenge in the control programs for cystic echinococcosis (CE) is ensuring government

commitment[108,109]. These programs require substantial effort and financial investment,

funding that should come from government sources, such as Ministries of Health and

Ministries of Agriculture, and participation of other sectors such as education and

environment[109,110]. Short-term programs spanning only a few years are inadequate; CE must

be treated as a chronic endemic disease requiring sustained efforts over many years[18,111].

Countries, such as Uruguay and Argentina, have been implementing control programs for

over 50 years with important successes but they continue to face challenges despite their

long-term commitment[30,112].

Others have conducted reviews on EG and its control. For ours, we used the PRISMA-ScR

framework and the Arksey and O'Malley method, focusing on studies in English, Spanish,

and Portuguese. Others have used various guidelines and checklists, including

PRISMA[15,113], MeSH[26], and Medline[18], to evaluate articles across multiple languages and

databases. We used MMAT for quality appraisal, while others used RCVS, CASP and JBI[114].

Despite the lack of detailed methodologies in other reviews on EG, they provide

comprehensive summaries of the determinants and control programs associated with EG

infection. A review[26] highlighted projects like HERACLES (Human Echinococcosis ReseArch

in Central and Eastern Societies)[115,116] and MEmE (Multi-centre study on *Echinococcus*

multilocularis and EG in Europe: development and harmonization of diagnostic methods in

the food chain)[117,118], which have created a comprehensive database with the latest

epidemiological data from various regions. Multiple reviews[18,26,119,120] agreed with us that

sheep vaccination emerged as a promising strategy to complement and reduce the time of

the control efforts. However, it is important to recognize that logistical and financial

challenges remain in endemic countries, impacting the effectiveness of these interventions.

Similar to our results[87,94], others have found that island control programs tend to have higher

success rates possibly due to easier disease containment and more manageable

populations[99]. Interestingly, one review suggested sustained vertical campaigns that include

treatment of dogs, community education, surveillance in rural areas, although they warn

about significant time and resources[99]. We found vertical programs with strict enforcement

measures in the Falklands and Cyprus[87,94], both with positive results; however, the insular

context might have played a bigger role in the success of those programs. Key challenges

reported in these reviews and also found in our review are reliance on rural dog owners for

implementing dog treatment, inadequate funding and staffing of programs, and political

instability or insufficient political will[6,18,119]. The One-Health approach is recommended to

address these issues effectively[120–122]. Other frequently encountered implementation barriers

that most studies fail to report are limited surveillance[71,81], followed by the presence of

ownerless dogs[60,81,89], and two barriers that are assumed common in many endemic

countries: geographic accessibility and the semi-nomadic lifestyle of some communities[73].

Multiple animal-targeting studies reviewed here have tested and refined interventions for the

main definitive EG host, the domestic dogs. Since the development of PZQ (Fig 4), an

effective cestocide for the mature and immature adult stages of EG[123], that drug has been

the primary intervention for dogs, with treatment schemes varying from monthly to quarterly,

depending on the disease burden in the area. Challenges for the effectiveness of PZQ

include maintaining treatment, achieving high coverage, owner compliance, and government

enforcement[18,124]. One of the fundamental causes for not achieving high coverage is the

inability to find the dog at the house to receive the treatment. Recent innovative interventions

involve advanced tools like geolocation devices to treat hotspots, smart collars for automatic

baiting, and dropping PZQ baits with drones[74,77,79], which could improve efficiency and

reduce costs in control campaigns. Currently, logistical costs are too high for sustained PZQ-

based control programs[125,126]. Some of the studies we discuss here report a payment from

the dog owners[127], others promote dog owners to buy PZQ in bulk to treat their animals[84],

other require an annual registration fee for the dog to support PZQ treatment among other

dog-related interventions[87], while in a few countries PZQ is provide free of cost to dog

owners[63,73,81].

From the beginning of PZQ and other oral treatments for dogs, palatability and acceptability

studies have been conducted to improve mass use of these drugs[128]. More recent studies

have focused on understanding reinfection rates after PZQ[125] and testing slow-release PZQ

formulations to reduce frequency of treatment[76,126]. A formulation that protects dogs for long

periods (similar to what is expected from a vaccine) would be a real game changer. Equally

important are studies on stakeholder acceptability of interventions. For example, some

studies found conflicting perspectives coming from breeders and their wifes, and local

authorities, and health providers related to EG control actions[38,129]. To enhance the

feasibility, sustainability, and ultimate success of elimination and control programs, it is

imperative to conduct implementation research[130,131] studies that delve into the agendas and

motivations of various stakeholders[132,133]. Understanding the perspectives and priorities of

these stakeholders can increase community engagement and inform the design and

implementation of more effective interventions[133]. Active participation from the community

ensures better acceptance and adherence to control measures, fostering a sense of

ownership and responsibility towards the program's goals[134,135]. This multifaceted program

would align well with the One Health approach[136–138] not only addressing the technical and

logistical challenges, but also building a supportive environment that can sustain long-term

efforts against the disease.

Our study had some limitations. The final set of articles included a wide range of study

designs and approaches, which led to significant heterogeneity in the data. This

heterogeneity made it challenging to summarize findings across studies. Differences in the

reported methods and results between studies made the classification of studies especially

challenging for the quality appraisal. As with other types of reviews, our scoping review
could be susceptible to publication bias, due to unpublished or inaccessible studies. Also,
we made a strong effort to balance breadth and depth; however, it is possible we prioritized
more breadth making it difficult to synthesize findings comprehensively. A challenge we
faced was the reduced number of studies included for full-text review. With sparse data,
generalizability may be limited and there may be a risk of over interpreting the significance of
findings. Moreover, this limited number of studies impeded identifying trends. Despite these
limitations, we conducted a rigorous quality assessment of the included studies and
implemented a detailed protocol to reduce subjectivity in study selection and data extraction.

Conclusion

In sum, the literature on control, prevention, or elimination of *E. granulosus sensu lato*
shows key advancements in diagnosis, treatment, and vaccines for the intermediate and
definitive hosts. However, progress remains inconsistent, particularly in endemic regions,
and many studies lack clear post-intervention outcomes, impeding the ability to inform future
programs. Standardization in the reporting of studies is necessary for comparability of
results and scaling-up of interventions. Effective EG control requires sustained government
commitment, funding, and active participation from various sectors, including health,
agriculture, and education. Long-term programs are necessary, as demonstrated by the
decades-long efforts in Uruguay and Argentina. Innovative strategies, such as geolocation
devices and drones for PZQ baiting, show promise but face logistical and financial
challenges. To enhance the feasibility and sustainability of elimination and control programs,
implementation research focused on understanding stakeholders' agendas and increasing
community engagement is crucial. Multi-pronged integrative One Health approaches are
essential for overcoming the logistical, economical, and political challenges of sustaining
long-term efforts for echinococcosis control.

Acknowledgments:

We are grateful to Fredy Daniel Bustamante Villanueva for his support during article

retrieval.

References

1. Centers for Disease Control and Prevention. Echinococcosis. May 13, 2023. Accessed April 11, 2024. https://www.cdc.gov/parasites/echinococcosis/index.html

2. Vuitton DA, McManus DP, Rogan MT, et al. International consensus on terminology to be used in the field of echinococcoses. *Parasite*. 27:41. doi:10.1051/parasite/2020024

3. World Health Organization. Echinococcosis. May 17, 2021. Accessed April 11, 2024. https://www.who.int/news-room/fact-sheets/detail/echinococcosis

4. Alishani M, Sherifi K, Rexhepi A, et al. The impact of socio-cultural factors on transmission of *Taenia spp.* and *Echinococcus granulosus* in Kosovo. *Parasitology*. 2017;144(13):1736-1742. doi:10.1017/S0031182017000750

5. Espinoza MSA. *EVALUATION AND RECOMMENDATIONS FOR THE CONTROL OF CYSTIC ECHINOCOCCOSIS IN WALES*. University of Glasgow; 2015. https://renati.sunedu.gob.pe/bitstream/sunedu/152953/1/Aybar_%20Espinoza_Mariel_M.pdf

6. Moro P, Schantz PM. Echinococcosis: a review. *Int J Infect Dis*. 2009;13(2):125-133. doi:10.1016/j.ijid.2008.03.037

7. Valderrama Pomé AA, Mamani Puma G, Uzuriaga Fuentes FJ. Determination of copro-prevalence of *Echinococcus granulosus* and associated factors in domestic dogs: a household cross-sectional study in Huancarama, Peru. *Austral J Vet Sci*. 2023;55(3):167-175. doi:10.4206/ajvs.553.02

8. Bristow BN, Lee S, Shafir S, Sorvillo F. Human Echinococcosis Mortality in the United States, 1990–2007. *PLoS Negl Trop Dis*. 2012;6(2):e1524. doi:10.1371/journal.pntd.0001524

9. Finlay JC, Speert DP. Sylvatic hydatid disease in children: case reports and review of endemic *Echinococcus granulosus* infection in Canada and Alaska. *Pediatr Infect Dis J*. 1992;11(4):322-326.

10. Moore RD, Urschel JD, Fraser RE, Nakai SS, Geeraert AJ. Cystic hydatid lung disease

in Northwest Canada. *JCC*. 1994;37(1):20-22.

11. Casulli A, Abela-Ridder B, Petrone D, et al. Unveiling the incidences and trends of the

neglected zoonosis cystic echinococcosis in Europe: a systematic review from the

MEmE project. *Lancet Infect Dis*. 2023;23(3):e95-e107. doi:10.1016/S1473-

3099(22)00638-7

12. European Centre for Disease Prevention and Control. *Echinococcosis Annual*

Epidemiological Report for 2020. ECDC; 2020:8.

https://www.ecdc.europa.eu/sites/default/files/documents/echinococcosis-annual-

epidemiolpgical-report-2020.pdf

13. Infectious Agents Surveillance Report. Echinococcosis in Japan, 1999-2018.

2019;40(3):33-34.

14. Ghatee MA, Nikaein K, Taylor WR, et al. Environmental, climatic and host population

risk factors of human cystic echinococcosis in southwest of Iran. *BMC Public Health*.

2020;20(1):1611. doi:10.1186/s12889-020-09638-w

15. Otero-Abad B, Torgerson PR. A Systematic Review of the Epidemiology of

Echinococcosis in Domestic and Wild Animals. Garcia HH, ed. *PLoS Negl Trop Dis*.

2013;7(6):e2249. doi:10.1371/journal.pntd.0002249

16. Yang YR. Impact of anthropogenic and natural environmental changes on

Echinococcus transmission in Ningxia Hui Autonomous Region, the People's Republic

of China. Accessed April 26, 2024.

https://parasitesandvectors.biomedcentral.com/articles/10.1186/1756-3305-5-146

17. Budke CM, Deplazes P, Torgerson PR. Global Socioeconomic Impact of Cystic

Echinococcosis. *Emerg Infect Dis*. 2006;12(2):296-303. doi:10.3201/eid1202.050499

18. Craig PS, McManus DP, Lightowlers MW, et al. Prevention and control of cystic

echinococcosis. *Lancet Infect Dis*. 2007;7(6):385-394. doi:10.1016/S1473-

3099(07)70134-2

19. Giri S, Parija SC. A review on diagnostic and preventive aspects of cystic

echinococcosis and human cysticercosis. *Trop Parasitol*. 2012;2(2):99-108.

doi:10.4103/2229-5070.105174

20. Sarkar S, Roy H, Saha P, Sengupta M, Sarder K, Sengupta M. Cystic echinococcosis:

A neglected disease at usual and unusual locations. *Trop Parasitol*. 2017;7(1):51-55.

doi:10.4103/tp.TP_55_16

21. Organization WH. *Working to Overcome the Global Impact of Neglected Tropical*

Diseases: First WHO Report on Neglected Tropical Diseases. World Health

Organization; 2010. Accessed April 26, 2024. https://iris.who.int/handle/10665/44440

22. Cai J, Yang K, Chen Q, et al. The impact of echinococcosis interventions on economic

outcomes in Qinghai Province of China: Evidence from county-level panel data. *Front*

Vet Sci. 2023;10. doi:10.3389/fvets.2023.1068259

23. World Health Organization. Neglected tropical diseases, hidden successes, emerging

opportunities. *Mal Trop Négligées Succès Ignorés Nouv Oppor*.

2009;(WHO/HTM/NTD/2009.2). Accessed June 16, 2024.

https://iris.who.int/handle/10665/44214

24. Reid S. The rural determinants of health: using critical realism as a theoretical

framework. *Rural Remote Health*. 2019;19(3):5184. doi:10.22605/RRH5184

25. Tamarozzi F, Deplazes P, Casulli A. Reinventing the Wheel of *Echinococcus*

granulosus sensu lato Transmission to Humans. *Trends Parasitol*. 2020;36(5):427-434.

doi:10.1016/j.pt.2020.02.004

26. Hogea MO, Ciomaga BF, Muntean MM, Muntean AA, Popa MI, Popa GL. Cystic

Echinococcosis in the Early 2020s: A Review. *Trop Med Infect Dis*. 2024;9(2):36.

doi:10.3390/tropicalmed9020036

27. Ma T, Wang Q, Hao M, et al. Epidemiological characteristics and risk factors for cystic

and alveolar echinococcosis in China: an analysis of a national population-based field

survey. *Parasit Vectors*. 2023;16(1):181. doi:10.1186/s13071-023-05788-z

28. Omadang L, Chamai M, Ejobi F, Erume J, Oba P, Ocaido M. Prevalence of cystic

echinococcosis among livestock in pastoral and agro-pastoral areas in Uganda.

Parasitology. 2023;151(1):68-76. doi:10.1017/S0031182023001154

29. Othieno E, Okwi AL, Mupere E, et al. Risk factors associated with cystic

echinococcosis in humans in selected pastoral and agro-pastoral areas of Uganda. *Int*

J One Health. 2017;3:1-6. doi:10.14202/IJOH.2017.1-6

30. Uchiumi L, Mujica G, Araya D, et al. Prevalence of human cystic echinococcosis in the

towns of Ñorquinco and Ramos Mexia in Rio Negro Province, Argentina, and direct risk

factors for infection. *Parasit Vectors*. 2021;14(1):262. doi:10.1186/s13071-021-04753-y

31. World Health Organization. WHO/OIE Manual on echinococcosis in humans and

animals. Published online 2001. Accessed May 15, 2024.

https://www.who.int/publications-detail-redirect/929044522X

32. Larrieu E, Gavidia CM, Lightowelers MW. Control of cystic echinococcosis: Background

and prospects. 2019;66(8). doi:10.1111/zph.12649

33. Wang Q, Zhong B, Yu W, et al. Assessment of a 10-year dog deworming programme

on the transmission of *Echinococcus multilocularis* in Tibetan communities in Sichuan

Province, China. *Int J Parasitol*. 2021;51(2):159-166. doi:10.1016/j.ijpara.2020.08.010

34. Yang S, Xiao N, Li J, et al. Reducing Canine *Echinococcus* Infection with Smart

Deworming Collars — Tibet, China, June–November, 2020. *China CDC Wkly*.

2020;2(51):979-982. doi:10.46234/ccdcw2020.265

35. Irabedra P, Ferreira C, Sayes J, et al. Control programme for cystic echinococcosis in

Uruguay. *Mem Inst Oswaldo Cruz*. 2016;111:372-377. doi:10.1590/0074-02760160070

36. Kachani M, Heath D. Dog population management for the control of human

echinococcosis. *Acta Trop*. 2014;139:99-108. doi:10.1016/j.actatropica.2014.05.011

37. Red Nacional de Vigilancia Epidemiológica, Instituto de Salud Carlos III, CIBER

Epidemiología y Salud Pública, Ministerio de Economía y Competitividad, Ministerio de

Sanidad, Servicios Sociales e Igualdad. Protocolo de Vigilancia de Hidatidosis. In:

Protocolos de la Red Nacional de Vigilancia Epidemiológica. Red Nacional de

Vigilancia Epidemiológica. Instituto de Salud Carlos III; 2013.

doi:10.4321/repisalud.5345

38. Saadi A, Antoine-Moussiaux N, Sahibi H, Filali H, Marcotty T, Thys S. Feasibility and

acceptability of a new integrated approach to control cystic echinococcosis in Morocco:

Vaccination of sheep and anthelmintic treatment of dogs. *Prev Vet Med*.

2021;192:105373. doi:10.1016/j.prevetmed.2021.105373

39. Altintas NA, Altintas NU, Sarica Yilmaz O, Akil M, Akdur Ozturk E, Unver A.

Educational Intervention for the Awareness Improvement and Control Programme

Design on Echinococcosis in Izmir, Turkey. *Helminthologia*. 2021;58(2):152-161.

doi:10.2478/helm-2021-0013

40. Pérez A, Costa MT, Gustavo C, et al. Vigilancia epidemiológica de la equinococcosis

quística en perros, establecimientos ganaderos y poblaciones humanas en la provincia

de Río Negro. *Med B Aires*. 2006;66(3):193-200.

41. World Health Organization. Improving surveillance data on cystic echinococcosis.

Accessed April 11, 2024. https://www.who.int/activities/improving-surveillance-data-on-

cystic-echinococcosis

42. Zanini F, Suárez C, Pérez H, Elissondo MC. Epidemiological surveillance of cystic

echinococcosis in rural population of Tierra del Fuego, Argentina, 1997–2006. *Parasitol*

Int. 2009;58(1):69-71. doi:10.1016/j.parint.2008.10.004

43. Del Carpio M, Mercapide CH, Salvitti JC, et al. Early Diagnosis, Treatment and Follow-

Up of Cystic Echinococcosis in Remote Rural Areas in Patagonia: Impact of Ultrasound

Training of Non-Specialists. *PLoS Negl Trop Dis*. 2012;6(1):e1444.

doi:10.1371/journal.pntd.0001444

44. Cringoli G, Pepe P, Bosco A, et al. An integrated approach to control Cystic

Echinococcosis in southern Italy. *Vet Parasitol*. 2021;290:109347.

doi:10.1016/j.vetpar.2021.109347

45. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic

review or scoping review? Guidance for authors when choosing between a systematic

or scoping review approach. *BMC Med Res Methodol*. 2018;18:143.

46. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc*

Res Methodol. Published online February 2005:19-32.

47. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.

Implement Sci. 2010;5:69. doi:10.1186/1748-5908-5-69

48. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for

conducting systematic scoping reviews. *JBI Evid Implement*. 2015;13(3):141-146.

doi:10.1097/XEB.0000000000000050

49. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-

ScR): Checklist and Explanation. *Ann Intern Med*. Published online September 4, 2018.

doi:10.7326/M18-0850

50. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT)

version 2018 for information professionals and researchers. *Educ Inf*. 2018;34(4):285-

291. doi:10.3233/EFI-180221

51. Hong QN, Pluye P, Fàbregues S, et al. Mixed methods appraisal tool (MMAT), version

2018 user guide. Published online 2018.

http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_20

18_criteria-manual_2018-08-01_ENG.pdf

52. Hong QN, Pluye P, Fàbregues S, et al. Reporting the results of the MMAT (version

2018). Published online 2018.

http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_20

18_criteria-manual_2018-08-01_ENG.pdf

53. Hernández Mira GM, Barros Fontes I, Ribeiro Cid A, Silveira A, Carola Espiguinha

Cortes H. Rastreos del grupo de lucha contra la equinococosis-hidatidosis en los

municipios de Elvas y Alandroal. *Rev Lab Clínico*. 2008;1(3):100-105.

doi:10.1016/j.labcli.2008.07.003

54. Pariona-Díaz A, Huamán-Albites M, Ureta-Jurado R, Huaman-Alvites O. Nivel de

conocimiento sobre Hidatidosis Humana y medidas preventivas tras la aplicación de un

Programa. *Enferm Univ*. 2018;15(3):284-293.

55. Castillo-Montes M, Lagos Kramm A, Cortés Sepúlveda M. Intervención educativa en

una enfermedad desatendida: hidatidosis/ equinococosis quística en escolares del

norte de Chile. *Rev Chil Infectol*. 2023;40(5):505-513. doi:10.4067/s0716-

10182023000500505

56. Condie SJ, Crellin JR, Andersen FL, Schantz PM. Participation in a community

program to prevent hydatid disease. *Public Health*. 1981;95(1):28-35.

doi:10.1016/S0033-3506(81)80097-2

57. Ducrotoy MJ, Yahyaoui Azami H, El Berbri I, et al. Integrated health messaging for

multiple neglected zoonoses: Approaches, challenges and opportunities in Morocco.

Acta Trop. 2015;152:17-25. doi:10.1016/j.actatropica.2015.08.011

58. Larrieu E, Frider B, Andreani G, Andreani G, Aquino A, De La Fuente R. Hidatidosis

humana: ecografía de campo para la determinación de grupos de alto riesgo en la

evaluación de un programa de control. *Rev Inst Med trop São Paulo*. 1989;31(4):267-

270. doi:https://doi.org/10.1590/S0036-46651989000400010

59. Meldrum GK, McConnell JD. The Control of Hydatid Disease in Tasmania. *Aust Vet J*.

1968;44(5):212-217. doi:10.1111/j.1751-0813.1968.tb09086.x

60. Cabrera PA, Lloyd S, Haran G, et al. Control of *Echinococcus granulosus* in Uruguay:

evaluation of different treatment intervals for dogs. *Vet Parasitol*. 2002;103(4):333-340.

doi:10.1016/S0304-4017(01)00603-3

61. Oku Y, Malgor R, Benavidez U, Carmona C, Kamiya H. Control program against

hydatidosis and the decreased prevalence in Uruguay. *Int Congr Ser*. 2004;1267:98-

104. doi:10.1016/j.ics.2004.01.087

62. Farias LN, Malgor R, Cassaravilla C, Bragança C, de la Rue ML. Echinococcosis in

southern Brazil: efforts toward implementation of a control program in Santana do

724   Livramento, Rio Grande do Sul. *Rev Inst Med Trop Sao Paulo*. 2004;46(3):153-156.

725   doi:10.1590/s0036-46652004000300006

726 63. Wang L, Gongsang Q, Pang H, et al. Assessment of echinococcosis control in Tibet

727   Autonomous Region, China. *Infect Dis Poverty*. 2022;11:59. doi:10.1186/s40249-022-

728   00987-9

729 64. Montalvo R, Huiza A, Nuñez V, et al. Results And Epidemiological Impact of The

730   Directly Observed Antiparasitic Treatment For Canine Echinococcosis. Published

731   online January 18, 2022. doi:10.21203/rs.3.rs-1205919/v1

732 65. Larrieu E, Herrero E, Mujica G, et al. Pilot field trial of the EG95 vaccine against ovine

733   cystic echinococcosis in Rio Negro, Argentina: early impact and preliminary data. *Acta*

734   *Trop*. 2013;127(2):143-151. doi:10.1016/j.actatropica.2013.04.009

735 66. Larrieu E, Mujica G, Araya D, et al. Pilot field trial of the EG95 vaccine against ovine

736   cystic echinococcosis in Rio Negro, Argentina: 8 years of work. *Acta Trop*. 2019;191:1-

737   7. doi:10.1016/j.actatropica.2018.12.025

738 67. Labanchi JL, Poggio TV, Gutiérrez A, et al. Analysis of vaccination strategy against

739   cystic echinococcosis developed in the Province of Río Negro, Argentina: 12 years of

740   work. *Vet Parasitol*. 2022;310:109790. doi:10.1016/j.vetpar.2022.109790

741 68. Gädicke P, Heath D, Medina-Brunet A, et al. Assessment of the Vaccination Program

742   against Cystic Echinococcosis in Sheep in the Pehuenche Community of Central Chile.

743   *Anim Open Access J MDPI*. 2022;12(6):679. doi:10.3390/ani12060679

744 69. Amarir F, Rhalem A, Sadak A, et al. Control of cystic echinococcosis in the Middle

745   Atlas, Morocco: Field evaluation of the EG95 vaccine in sheep and cesticide treatment

746   in dogs. *PLoS Negl Trop Dis*. 2021;15(3):e0009253. doi:10.1371/journal.pntd.0009253

747 70. Kummeneje K, Rognerud B, Korbi K. Echinococcosis in Slaughtered Reindeer

748   (Rangifer Tarandus) In Northern Norway. Preliminary Results of a Combat/Eradication

749   Program. *Acta Vet Scand*. 1981;22(3):592-593. doi:10.1186/BF03548683

750 71. Economides P, Christofi G. Evaluation of control programmes for

echinococcosis/hydatidosis in Cyprus. 2000;19(3):784. doi:10.20506/rst.19.3.1252

72. Macpherson CNL, Wachira TM, Zeyhle E, Romig T, Macpherson C. Hydatid disease:

Research and control in Turkana, IV. The pilot control programme. *Trans R Soc Trop*

Med Hyg. 1986;80(2):196-200. doi:10.1016/0035-9203(86)90007-6

73. Van Kesteren F, Mastin A, Torgerson P, Mytynova B, Craig P. Evaluation of the impact

of 2 years of a dosing intervention on canine echinococcosis in the Alay Valley,

Kyrgyzstan. *Parasitology*. 2017;44(10):1328-1337.

74. Yu Q, Xiao N, Yang SJ, Han S. Deworming of stray dogs and wild canines with

praziquantel-laced baits delivered by an unmanned aerial vehicle in areas highly

endemic for echinococcosis in China. *Infect Dis Poverty*. 2017;6(1):117.

doi:10.1186/s40249-017-0329-8

75. Yang YR, McManus DP, Huang Y, Heath DD. *Echinococcus granulosus* Infection and

Options for Control of Cystic Echinococcosis in Tibetan Communities of Western

Sichuan Province, China. *PLoS Negl Trop Dis*. 2009;3(4):e426.

doi:10.1371/journal.pntd.0000426

76. Wei J, Cheng F, Qun Q, et al. Epidemiological evaluations of the efficacy of slow-

released praziquantel-medicated bars for dogs in the prevention and control of cystic

echinococcosis in man and animals. *Parasitol Int*. 2005;54(4):231-236.

doi:10.1016/j.parint.2005.06.002

77. Yang SJ, Xiao N, Li JZ, et al. A remote management system for control and

surveillance of echinococcosis: design and implementation based on internet of things.

Infect Dis Poverty. 2021;10(1):50. doi:10.1186/s40249-021-00833-4

78. Berlinguer F, Ahmed F, Tamponi C, et al. Help from the sky: Can vultures contribute to

Cystic Echinococcosis control in endemic areas? *PLoS Negl Trop Dis*.

2021;15(7):e0009615. doi:10.1371/journal.pntd.0009615

79. Nocerino M, Pepe P, Bosco A, et al. An innovative strategy for deworming dogs in

Mediterranean areas highly endemic for cystic echinococcosis. *Parasit Vectors*.

2024;17(1):86. doi:10.1186/s13071-024-06184-x

80.   Larrieu E, Costa MT, Cantoni G, et al. Control de la hidatidosis en la provincia de Río

Negro, Argentina: evaluación actividades de atención veterinaria (1). *Rev Sanid Hig*

Publica. 1994;68(1):197-202.

81.   Larrieu E, Costa MT, Cantoni G, et al. Control program of hydatid disease in the

province of Río Negro Argentina. 1980-1997. *Bol Chil Parasitol*. 2000;55(3-4):49-53.

doi:10.4067/s0365-94022000000300003

82.   Arezo M, Mujica G, Uchiumi L, et al. Identification of potential "hot spots" of cystic

echinococcosis transmission in the province of Río Negro, Argentina. *Acta Trop*.

2020;204:105341. doi:10.1016/j.actatropica.2020.105341

83.   Chacon T. Estado de situación sobre Hidatidosis en Chile y la región de Aysen.

MarcoAcuña Briones, SEREMI de Salud, Región de Aysen. "Seminario de hidatidosis:

Una Salud, Presente y Futuro." November 8, 2023. Accessed February 19, 2024.

https://hidatidosis.ar/wp-content/uploads/2023/11/Coyhaique-Tomas-Chacon.pdf

84.   Apt W, Pérez C, Galdamez E, et al. Equinococosis/hidatidosis en la VII Región de

Chile: diagnóstico e intervención educativa. *Rev Panam Salud Publica*. 2000;7(1).

Accessed May 14, 2024. https://iris.paho.org/handle/10665.2/8872

85.   Andersen FL, Crellin JR, Nichols CR, Schantz PM. Evaluation of a Program to Control

Hydatid Disease in Central Utah. *Gt Basin Nat*. 1983;43(1):65-72.

86.   Gemmell MA. The Styx field-trial. A study on the application of control measures

against hydatid disease caused by *Echinococcus granulosus*. *Bull World Health Organ*.

1968;39(1):73-100.

87.   Polydorou K. The anti-echinococcosis campaign in Cyprus. *Trop Anim Health Prod*.

1977;9(3):141-146. doi:10.1007/BF02236587

88.   Lloyd S, Walters TM, Craig PS. Use of sentinel lambs to survey the effect of an

education programme on control of transmission of *Echinococcus granulosus* in South

Powys, Wales. *Bull World Health Organ*. 1998;76(5):469-473.

89. El Berbri I, Mahir W, Shaw A, et al. Evaluation of integrated control of three dog

transmitted zoonoses: Rabies, visceral leishmaniasis and cystic echinococcosis, in

Morocco. *Acta Trop.* 2020;212:105689. doi:10.1016/j.actatropica.2020.105689

90. Jiménez S, Pérez A, Gil H, Schantz P, Ramalle E, Juste R. Progress in control of cystic

echinococcosis in La Rioja, Spain: decline in infection prevalences in human and

animal hosts and economic costs and benefits. *Acta Trop.* 2002;83(3):213-221.

doi:10.1016/s0001-706x(02)00091-8

91. Gimeno Ortiz A, Calero Carretero R, Carmona Carmona E, Caldera Domínguez J.

Evaluación del programa de lucha contra la hidatidosis-equinococosis en Extremadura,

tras siete años de actuaciones. *Rev Sanid E Hig Pública.* 1991;65(5):451-461.

92. Zhang W, Zhang Z, Yimit T, et al. A Pilot Study for Control of Hyperendemic Cystic

Hydatid Disease in China. *PLoS Negl Trop Dis.* 2009;3(10):e534.

doi:10.1371/journal.pntd.0000534

93. Yu Q, Xiao N, Han S, Tian T, Zhou XN. Progress on the national echinococcosis

control programme in China: analysis of humans and dogs population intervention

during 2004-2014. *Infect Dis Poverty.* 2020;9(1):137. doi:10.1186/s40249-020-00747-7

94. West D. *Understanding Transmission and Control of Cystic Echinococcosis and Other*

Taeniid Infections in the Falkland Islands. 2021. Accessed May 23, 2024.

https://salford-repository.worktribe.com/output/1332525/understanding-transmission-

and-control-of-cystic-echinococcosis-and-other-taeniid-infections-in-the-falkland-islands

95. Lightowlers MW, Jensen O, Fernandez E, et al. Vaccination trials in Australia and

Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. *Int J*

Parasitol. 1999;29(4):531-534. doi:10.1016/S0020-7519(99)00003-X

96. Allan JC, Craig PS, Garcia Noval J, et al. Coproantigen detection for immunodiagnosis

of echinococcosis and taeniasis in dogs and humans. *Parasitology.* 1992;104 (Pt

2):347-356. doi:10.1017/s0031182000061801

97. Deplazes P, Gottstein B, Eckert J, Jenkins DJ, Ewald D, Jimenez-Palacios S. Detection

of *Echinococcus* coproantigens by enzyme-linked immunosorbent assay in dogs,

dingoes and foxes. *Parasitol Res*. 1992;78(4):303-308. doi:10.1007/BF00937088

98.　Eckert J, Thompson RCA. Historical Aspects of Echinococcosis. *Adv Parasitol*.

2017;95:1-64. doi:10.1016/bs.apar.2016.07.003

99.　Craig PS, Larrieu E. Control of cystic echinococcosis/hydatidosis: 1863-2002. *Adv*

Parasitol. 2006;61:443-508. doi:10.1016/S0065-308X(05)61011-1

100.　Ebrahimipour M, Budke CM, Harandi MF. Control of Cystic Echinococcosis in Iran:

Where Do We Stand? *Trends Parasitol*. 2020;36(7):578-581.

doi:10.1016/j.pt.2020.04.007

101.　Larrieu E, Zanini F. Critical analysis of cystic echinococcosis control programs and

praziquantel use in South America, 1974-2010. *Rev Panam Salud Publica Pan Am J*

Public Health. 2012;31(1):81-87. doi:10.1590/s1020-49892012000100012

102.　Romig T, Omer RA, Zeyhle E, et al. Echinococcosis in sub-Saharan Africa: emerging

complexity. *Vet Parasitol*. 2011;181(1):43-47. doi:10.1016/j.vetpar.2011.04.022

103.　Battelli G. Echinococcosis: costs, losses and social consequences of a neglected

zoonosis. *Vet Res Commun*. 2009;33 Suppl 1:47-52. doi:10.1007/s11259-009-9247-y

104.　Moro PL, Budke CM, Schantz PM, Vasquez J, Santivañez SJ, Villavicencio J.

Economic Impact of Cystic Echinococcosis in Peru. *PLoS Negl Trop Dis*.

2011;5(5):e1179. doi:10.1371/journal.pntd.0001179

105.　Widdicombe J, Basáñez MG, Entezami M, Jackson D, Larrieu E, Prada JM. The

economic evaluation of Cystic echinococcosis control strategies focused on zoonotic

hosts: A scoping review. *PLoS Negl Trop Dis*. 2022;16(7):e0010568.

doi:10.1371/journal.pntd.0010568

106.　Kolopack PA, Parsons JA, Lavery JV. What Makes Community Engagement

Effective?: Lessons from the Eliminate Dengue Program in Queensland Australia.

PLoS Negl Trop Dis. 2015;9(4):e0003713. doi:10.1371/journal.pntd.0003713

107.　Questa K, Das M, King R, et al. Community engagement interventions for

859  communicable disease control in low- and lower- middle-income countries: evidence

860  from a review of systematic reviews. *Int J Equity Health*. 2020;19(1):51.

861  doi:10.1186/s12939-020-01169-5

862 108. Saadi A, Sahibi H, Thys S, et al. Stakeholder analysis to improve the national control

863  program of cystic echinococcosis in Morocco. *Prev Vet Med*. 2021;186:105227.

864  doi:10.1016/j.prevetmed.2020.105227

865 109. World Health Organization. Report of the WHO informal working group on cystic and

866  alveolar echninococcosis surveillance, prevention and control. Published online June 6,

867  2011:25.

868 110. Larrieu E, Organization PAH. Prevention and Control of Hydatidosis at Local Level:

869  South American Initiative for the Control and Surveillance of Cystic

870  Echinococcosis/Hydatidosis. *Ser Man Téc*. 2017;18. Accessed June 28, 2024.

871  https://iris.paho.org/handle/10665.2/49043

872 111. Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS, eds. *WHO/OIE Manual on*

873  *Echinococcosis in Humans and Animals: A Zoonosis of Global Concern*. World

874  Organisation for Animal Health; 2001.

875 112. Poggio T, Jensen O, Saravia T, et al. Past and Future Methods for Controlling

876  *Echinococcus granulosus* in South America. *Int J Echinococcoses*. 2022;1(1):54.

877  doi:10.5455/IJE.2021.11.07

878 113. Wolfe CM, Barry A, Campos A, et al. Control, elimination, and eradication efforts for

879  neglected tropical diseases in the World Health Organization African region over the

880  last 30 years: A scoping review. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*.

881  2024;141:106943. doi:10.1016/j.ijid.2024.01.010

882 114. Christofi E. Cystic Echinococcosis: An Impact Assessment of Prevention Programs in

883  Endemic Developing Countries in Africa, Central Asia, and South America. *J Zool Syst*

884  *Evol Res*. 2022;2022(1):8412718. doi:10.1155/2022/8412718

885 115. CORDIS. Final Report Summary - HERACLES (Human cystic Echinococcosis

ReseArch in CentraL and Eastern Societies) | FP7. CORDIS | European Commission.

April 11, 2019. Accessed June 28, 2024.

https://cordis.europa.eu/project/id/602051/reporting

116. HERACLES. Project background. 2014. Accessed June 28, 2024. http://www.heracles-

fp7.eu/background.html

117. Casulli A. Final Report. Published online November 24, 2022.

doi:10.5281/zenodo.7357984

118. One Health EJP. MEmE: Multi-centre study on *Echinococcus multilocularis* and

Echinococcus granulosus s.l. in Europe: development and harmonisation of diagnostic

methods in the food chain. https://onehealthejp.eu. Accessed June 28, 2024.

https://onehealthejp.eu/projects/emerging-threats/jrp-meme

119. Eckert J, Conraths FJ, Tackmann K. Echinococcosis: an emerging or re-emerging

zoonosis? *Int J Parasitol*. 2000;30(12-13):1283-1294. doi:10.1016/s0020-

7519(00)00130-2

120. Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: Advances in the 21st Century. *Clin*

Microbiol Rev. 2019;32(2):e00075-18. doi:10.1128/CMR.00075-18

121. Gharbi M, Giraudoux P. Cystic echinococcosis (*Echinococcus granulosus sensu lato*

infection) in Tunisia, a One Health perspective for a future control programme. *Parasite*

Paris Fr. 2024;31:30. doi:10.1051/parasite/2024029

122. Mujica G, Uchiumi L, Araya D, et al. The Diagnosis, Treatment, Surveillance and

Control of Cystic Echinococcosis in the Province of Rio Negro: The "One-Health"

Model. *Parasitologia*. 2021;1(4):177-187. doi:10.3390/parasitologia1040019

123. Lightowlers MW, Gasser RB, Hemphill A, et al. Advances in the treatment, diagnosis,

control and scientific understanding of taeniid cestode parasite infections over the past

50 years. *Int J Parasitol*. 2021;51(13):1167-1192. doi:10.1016/j.ijpara.2021.10.003

124. Dakkak A. Echinococcosis/hydatidosis: a severe threat in Mediterranean countries. *Vet*

Parasitol. 2010;174(1-2):2-11. doi:10.1016/j.vetpar.2010.08.009

125. Borhani M, Mohammadi MA, Entezami M, et al. Reinfection of farm dogs following

praziquantel treatment in an endemic region of cystic echinococcosis in southeastern

Iran. *PLoS Negl Trop Dis.* 2024;18(3):e0011939. doi:10.1371/journal.pntd.0011939

126. Jiang B, Zhou XN, Zhang HB, Tao Y, Huo LL, Liu N. Slow-release praziquantel for

dogs: presentation of a new formulation for echinococcosis control. *Infect Dis Poverty.*

2017;6:140. doi:10.1186/s40249-017-0357-4

127. Turnes AL. La hidatidosis como problema de salud pública: una mirada histórica. In: *La*

hidatidosis como problema de salud pública: una mirada histórica. ; 2009:142.

Accessed July 2, 2024. https://search.bvsalud.org/gim/resource/pt/biblio-1253238

128. Gemmell MA, Johnstone PD, Oudemans G. The application of a food incorporating

praziquantel in the treatment and control of *Echinococcus granulosus* infections in

dogs. *Aust Vet J.* 1982;58(3):120-121. doi:10.1111/j.1751-0813.1982.tb00614.x

129. Saadi A, Antoine-Moussiaux N, Marcotty T, Thys S, Sahibi H. Using qualitative

approaches to explore the challenges of integrated programmes for zoonosis control in

developing countries: Example of hydatidosis control in Morocco. *Zoonoses Public*

Health. 2021;68(5):393-401. doi:10.1111/zph.12814

130. Allotey P, Reidpath DD, Ghalib H, Pagnoni F, Skelly WC. Efficacious, effective, and

embedded interventions: Implementation research in infectious disease control. *BMC*

Public Health. 2008;8(1):343. doi:10.1186/1471-2458-8-343

131. World Health Organization, UNICEF/UNDP/World Bank/WHO Special Programme for

Research and Training in Tropical Diseases. *Implementation Research for the Control*

of Infectious Diseases of Poverty: Strengthening the Evidence Base for the Access and

Delivery of New and Improved Tools, Strategies and Interventions. World Health

Organization; 2011. Accessed July 1, 2024. https://iris.who.int/handle/10665/75216

132. Binagwaho A, Frisch MF, Udoh K, et al. Implementation Research: An Efficient and

Effective Tool to Accelerate Universal Health Coverage. *Int J Health Policy Manag.*

2019;9(5):182-184. doi:10.15171/ijhpm.2019.125

133. Peters D, Tran N, Adam T, Alliance for Health Policy and Systems Research, World

Health Organization. *Implementation Research in Health: A Practical Guide / Edited by*

David Peters … [et Al]. World Health Organization; 2013. Accessed July 1, 2024.

https://iris.who.int/handle/10665/91758

134. Haldane V, Chuah FLH, Srivastava A, et al. Community participation in health services

development, implementation, and evaluation: A systematic review of empowerment,

health, community, and process outcomes. *PloS One*. 2019;14(5):e0216112.

doi:10.1371/journal.pone.0216112

135. Kale S, Shoyeb H, Vardhan S, et al. Addressing Cancer Disparities Through

Community Engagement: Lessons and Best Practices. *Cureus*. 2023;15(8).

doi:10.7759/cureus.43445

136. Aggarwal D, Ramachandran A. One Health Approach to Address Zoonotic Diseases.

Indian J Community Med Off Publ Indian Assoc Prev Soc Med. 2020;45(Suppl 1):S6.

doi:10.4103/ijcm.IJCM_398_19

137. Ghai RR, Wallace RM, Kile JC, et al. A generalizable one health framework for the

control of zoonotic diseases. *Sci Rep*. 2022;12. doi:10.1038/s41598-022-12619-1

138. Mubareka S, Amuasi J, Banerjee A, et al. Strengthening a One Health approach to

emerging zoonoses. *FACETS*. 2023;8:1-64. doi:10.1139/facets-2021-0190

139. World Health Organization. Global Distribution of Cystic Echinococcosis 2011. 2011.

https://www.who.int/docs/default-source/ntds/echinococcosis/global-distribution-of-

cystic-echinococcosis-2011.pdf?sfvrsn=15bf8521_4

140. Batham EJ. Testing arecoline hydrobromide as an anthelminthic for hydatid worms in

dogs. *Parasitology*. 1946;37(3-4):185-191. doi:10.1017/S0031182000013342

141. Blood BD, Moya V, Lelijveld JL. Evaluation of selected drugs for the treatment of

canine echinococcosis. *Bull World Health Organ*. 1968;39(1):67-72.

142. Cringoli G, Rinaldi L, Musella V, et al. Geo-referencing livestock farms as tool for

studying cystic echinococcosis epidemiology in cattle and water buffaloes from

967  southern Italy. *Geospatial Health*. 2007;2(1):105-111. doi:10.4081/gh.2007.259

968 143. Gemmell MA, Oudemans G. The effect of nitroscanate on *Echinococcus granulosu*s

969  and *Taenia hydatigena* infections in dogs. *Res Vet Sci*. 1975;19(2):217-219.

970 144. Roberts MG, Lawson JR, Gemmell MA. Population dynamics in echinococcosis and

971  cysticercosis: mathematical model of the life-cycle of *Echinococcus granulosus*.

972  *Parasitology*. 1986;92 (Pt 3):621-641. doi:10.1017/s0031182000065495

 # Supporting information

 Appendix 1. Search Strategy

 Search Concepts

Echinococcus Granulosus	Strategies
Echinococcus	Prevention
Echinococcosis	Control
Echinococcoses	Preventive therapy
Echinococcus Infection	Preventive measures
Echinococcus Infections	Prophylaxis
Infection, Echinococcus	Therapeutic
Cystic Echinococcosis	Therapy
Cystic Echinococcoses	Treatment
Hydatidosis	Treatments
Hydatidoses	Elimination
Hydatid Cysts	Intervention
Hydatid Cyst	Early intervention
Hydatid Disease	Late intervention
Hydatid Diseases	Drug therapy
Echinococcus Granulosus Infection	Drug Therapies
	Pharmacotherapy

	Pharmacotherapies
	Vaccine
	Health Promotion
	Health Campaign
	Pest control
	Pest management

977   MEDLINE Search strategy:

978   1. Echinococcus Granulosus

979   2. Echinococcus

980   3. Echinococcosis

981   4. Echinococcoses

982   5. Echinococcus Infection

983   6. Echinococcus Infections

984   7. Infection, Echinococcus

985   8. Cystic Echinococcosis

986   9. Cystic Echinococcoses

987   10. Hydatidosis

988   11. Hydatidoses

989   12. Hydatid Cysts

990   13. Hydatid Cyst

991   14. Hydatid Disease

992   15. Hydatid Diseases

993   16. Echinococcus Granulosus Infection

994   17. 1-16 OR

995   18. Strategies

996   19. Prevention

997	20. Control
998	21. Preventive therapy
999	22. Preventive measures
1000	23. Prophylaxis
1001	24. Therapeutic
1002	25. Therapy
1003	26. Treatment
1004	27. Treatments
1005	28. Elimination
1006	29. Intervention
1007	30. Early intervention
1008	31. Late intervention
1009	32. Drug therapy
1010	33. Drug Therapies
1011	34. Pharmacotherapy
1012	35. Pharmacotherapies
1013	36. Vaccine
1014	37. Health Promotion
1015	38. Health Campaign
1016	39. Pest control
1017	40. Pest management
1018	41. 18-40 OR
1019	43. 17 AND 41

For MEDLINE and EMBASE we used MeSH subject heading.

Search terms used are centered on the concepts of '*Echinococcus granulosus* infection' and

'strategy'. The '*Echinococcus granulosus*' concept was built around synonyms (e.g., Hydatid

disease, Hydatid cyst). The "strategy" concept was broad and included terms covering all

types of interventions (e.g., Pest control, Therapy, Prevention). Qualified academic librarian

support was requested for identification of key words on the different databases and search

strategy refinement.

Figure 1. **Flowchart of the inclusion/exclusion process for studies on EG control**

interventions

1029
1030

1031 **Figure 2. Type of control intervention reported in the selected articles and**

1032 **intervention target within the EG life cycle.**[a]

1033

1034 [a] Intervention results are not included.

1035 **Figure 3. Global distribution of EG and cystic echinococcosis and studies**

1036

1037 Map Source: WHO 2011[139]

1038 **Figure 4. Timeline of the progress of EG control tools and the articles included in this**

1039 **review.**

1040

1041

1042

1043

1044

1045

1046

1047

1048 74,98,140–144

1049 **Appendix 2. Preferred Reporting Items for Systematic reviews and Meta-Analyses**

1050 **extension for Scoping Reviews (PRISMA-ScR) Checklist**

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	3-4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5-6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	5
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6-7, 57
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	6
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	54-56
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	6-7
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	7
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	7-8
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	7

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	8, 57
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	8
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	31
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	9, 13-15, 22-24
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	10-12, 16-21, 25-30
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	32-35
Limitations	20	Discuss the limitations of the scoping review process.	35-36
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	36
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	3